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Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the 
world1. Whilst the majority of PD patients have no known cause of the disease (‘sporadic’), 
around 5-10% of PD patients have genetic, familial forms of the disease2. LRRK2 and PINK1 
are two independent genes that respectively cause autosomal dominant and autosomal 
recessive forms of PD. They both encode protein kinases, which control signal transduction 
pathways through reversible phosphorylation of target proteins3. Current research aims to 
better understand and visualise the activation of both proteins and their associated pathways, 
to help uncover their role in PD pathogenesis.  
Aims 
The work detailed within this thesis is divided into two main projects ‘A’ and ‘B’, which 
respectively concern experiments I conducted in the LRRK2 and PINK1 signal transduction 
pathways.  
The main aim of Project A was to explore the activation of LRRK2 during infection of immune 
cells, in which I specifically focused on human peripheral blood neutrophils and mouse bone 
marrow derived macrophages (BMDMs). All infection experiments were conducted using P. 
aeruginosa, a Gram-negative opportunistic bacterium. In addition, I aimed to explore LRRK2 
activation within neutrophils isolated from the sputum samples of cystic fibrosis (CF) patients, 
who are frequently infected with strains of P. aeruginosa.  
The main aim of Project B was to investigate if activation of the PINK1/Parkin pathway could 
be detected within peripheral blood neutrophils, which would provide a quickly accessible and 
valuable human bio-source to interrogate PINK1 activity.  
Methods 
For Project A, I directly isolated peripheral blood neutrophils from whole blood donated by 
healthy volunteers, and extracted BMDMs from the femurs of sacrificed mice. I subsequently 
cultured and infected both cell types with standardised (PAO1) or uncharacterised clinical 
isolate strains of P. aeruginosa, over a time-course of 0-4 hours. In subsequent immunoblot 
analysis of cell lysates, I measured LRRK2 activity through use of the highly specific MJFF-
pRab10 antibody, which detects Rab10 phosphorylated by LRRK2 at Thr73. I also directly 
isolated neutrophils from the sputum of CF patients with chronic P. aeruginosa infection, and 
similarly analysed them for LRRK2 activity, using the MJFF-pRab10 antibody.  
5 
 
For Project B, I isolated peripheral blood neutrophils and treated them with the mitochondrial 
uncoupler CCCP for durations of 3-20 hours, and analysed neutrophil lysates for PINK1 
stabilisation through immunoblotting with the PINK1 (Novus) antibody. I also conducted PINK1 
immuno-precipitation (IP) experiments to confirm the presence of endogenous PINK1 in 
peripheral blood neutrophils. 
Results 
My results in Project A revealed an increase in LRRK2-dependent Rab10 phosphorylation 
during infection of human peripheral blood neutrophils with P. aeruginosa infection. 
Furthermore, sputum neutrophils isolated from CF patients revealed markedly elevated levels 
of LRRK2-dependent Rab10 phosphorylation compared to controls, suggesting that LRRK2 
activity may play an important role in human neutrophils during infection. In contrast, infection 
of mouse BMDMs with P. aeruginosa resulted in a progressive increase in LRRK2 Ser935 
phosphorylation, but did not result in any observable LRRK2-dependent Rab10 
phosphorylation. Further investigation into LRRK2 Ser935 phosphorylation in BMDMs 
following P. aeruginosa infection was shown to be mediated by the IKK family of kinases.  
My results in Project B revealed that endogenous PINK1 could not be defected in stimulated 
peripheral blood neutrophils with CCCP between 3-20 hour time-courses. 
Conclusions 
The results I obtained in Project A collectively indicated that the LRRK2 kinase is influenced 
by P. aeruginosa infection, of which key differences in its activation and phosphorylation of 
serine residues exist depending on immune cell type and human/mouse species. My results 
support future work which aims to explore the mechanisms behind P. aeruginosa infection and 
LRRK2 activity. Furthermore, my preliminary findings of LRRK2 activation within sputum 
neutrophils of CF patients with P. aeruginosa infection provides the basis for a future clinical 
study to assess the natural course of LRRK2 activation during CF infective exacerbations.  
Whilst my results in Project B did not demonstrate that PINK1 could be activated within 
peripheral blood neutrophils, future work could consider the use of different mitochondrial 
uncouplers, fractionation experiments, or more sensitive antibody readouts of the 
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MPP Mitochondrial processing peptidase 
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1. CHAPTER 1 - INTRODUCTION  
1.1 Parkinson’s Disease (PD) 
Parkinson’s disease (PD) is a progressive, age-related condition that is currently the second 
most common neurodegenerative disorder in the world4, affecting 2-3% of the population over 
65 years of age. Whilst it was first described over 200 years ago by James Parkinson within 
his landmark ‘Essay on the Shaking Palsy’ (Figure 1.1A), the understanding of PD continues 
to evolve5. At its core, PD is pathologically hallmarked by selective neurodegeneration of 
dopaminergic neurones projecting from the ventro-lateral tier of the substantia nigra pars 
compacta (SNpc) to the striatum, leading to continual depletion of the neurotransmitter 
dopamine (DA)6 (Figure 1.1B). In addition, autopsy findings reveal widespread accumulation 
of proteinaceous intracytoplasmic inclusions known as Lewy bodies and Lewy neurites, 
composed of α-Synuclein, within the few spared dopaminergic neurones7 (Figure 1.1C). 
Clinically, PD is diagnosed by the presence of cardinal motor symptoms corresponding to 
‘parkinsonism’, which according to the Movement Disorder Society (MDS) diagnostic criteria 
require the presence of bradykinesia (slowness of movement), in combination with at least 
one of rigidity and/or resting tremor8. In addition, other forms of parkinsonism must be 
excluded for a confirmed PD diagnosis, including atypical or drug-induced parkinsonism, as 
well as the presence of supportive PD criteria, and red flag exclusions8. Motor symptom onset 
usually begins in the late 50s and is commonly unilateral, with persistence of asymmetry 
throughout the disease. However, several systemic non-motor symptoms such as reduction 
or loss of smell (hyposmia), constipation, depression and sleep disturbances are also part of 
the PD prodrome9, and can precede the onset of motor symptoms by several years or even 
decades. Progressive PD disability and worsening quality of life is thus driven by a 
combination of continuing motor and non-motor symptoms, eventually resulting in cognitive 
decline and dementia in some individuals (Figure 1.1D). 
Sadly, there are still no curative treatments available to slow or prevent PD, thus current 
approaches aim to provide symptomatic benefit and improve quality of life. Key PD treatments 
include pharmacological substitution of striatal dopamine with ‘L-DOPA’, in addition to non-
dopaminergic approaches to address both motor and non-motor symptoms10. However, given 
the progressive nature of PD, the efficacy of pharmacological treatments eventually wear-off, 
and can additionally lead to disabling ‘off-target’ effects including unwanted dyskinetic 
movements. Deep brain stimulation (DBS) is an invasive interventional option available for 
those with L-DOPA related motor complications or drug refractory tremor, however is not 
without its own risks11. Moreover, it addresses only the symptoms of PD, rather than the 



















FIGURE 1.1: Combined schematic of Parkinson’s disease (PD) background, histopathology and 
timescale 
(A) First published description of PD as the ‘Shaking Palsy’ by James Parkinson in 1817. 
(B) PD neuropathology: Illustration of transverse midbrain sections of the basal ganglia, with particular focus 
on the substantia nigra pars compacta (SNpc) in a healthy individual (top) compared to an individual with PD 
(bottom). Top illustration shows healthy pigmentation of the SNpc from dopaminergic neurones, whilst bottom 
illustration shows significant depigmentation of the SNpc due to dopaminergic neurone loss, leading to PD 
symptoms. 
(C) PD histopathology: Photomicrograph of Lewy bodies (top) and Lewy neurites (bottom) found in 
remaining dopaminergic neurones within regions of the SNpc from a PD patient. Lewy bodies and neurites 
are intraneuronal inclusions predominantly formed of the protein alpha-synuclein. Top micrograph shows a 
60-times magnification of Lewy bodies whilst the bottom micrograph shows a 20-times magnification of Lewy 
neurites. Neuromelanin laden cells of the substantia nigra are seen in the background.  
(D) PD clinical progression: Schematic of the onset and progression of non-motor and motor PD symptoms 
over time in years (x-axis) against the degree of disease disability (y-axis), revealing growing disability with 
increasing years of PD. It should be noted that this timescale can considerably vary between PD individuals, 
and not all PD individuals will experience these symptoms. 
Figures 1.1A-C were publicly available for reuse and reproduction. Figure 1.1D is adapted upon Figure 5 
published in Poewe, W. et al. (2017) Parkinson disease. 




1.1.1 PD genetics  
Considerable years of research has revealed that PD is a clearly complex and multifactorial 
disease. The underlying molecular pathogenesis of PD is still being uncovered, however is 
thought to involve a myriad of pathways and mechanisms including mitochondrial dysfunction, 
oxidative stress, calcium homeostasis, α-Synuclein proteostasis and neuroinflammation6.  
Whilst the majority of PD patients are ‘sporadic’ with unknown aetiology, around 5-10% of 
patients have an inherited monogenetic form of the disease with Mendelian inheritance 
(‘familial PD’), which can be inherited in an autosomal dominant (AD) or autosomal recessive 
(AR) manner12. Generally, AD PD patients are characterised by late PD symptomatic onset in 
the late 50s (similar to sporadic PD patients), whilst AR PD patients tend to have an earlier 
PD onset <45 years13. So far, linkage analysis and genome wide association studies (GWAS) 
have identified 23 loci (PARK1-23) associated with PD, of which 13 have shown to be causal 
for PD, 3 which increase PD risk, and 7 in which the relationship with PD is currently unclear 
(Table 1). In addition, a further 92 common genetic risk loci and variants in sporadic PD 
patients have been revealed through GWAS studies14. Thus, a culminative combination of 
multiple common and rare genetic variants in addition to several environmental and stochastic 
factors are likely to be behind the majority of ‘sporadic’ PD patients. 
In the timeline of PD gene discovery, 2004 heralded ground-breaking findings of mutations in 
two independent genes, LRRK2 (PARK8)15 and PINK1 (PARK6)16, to be causally linked to PD 
(Table 1). Both genes encode a group of enzymes termed protein kinases, which cause post-
translational modifications (PTMs) of target proteins through the reversible addition of a 
covalently bound phosphate group onto the side chains of one of three amino acids; serine 
(Ser), threonine (Thr) or tyrosine (Tyr)17 (Figure 1.2). This integral process termed 
‘phosphorylation’ results in a conformational and functional change of the target protein, which 
can affect the regulation of downstream cellular processes including the cell cycle, growth, 
apoptosis and signal transduction pathways18. Research into the functional and biological 
importance of LRRK2 and PINK1 kinases and their signal transduction pathways have 








FIGURE 1.2  
FIGURE 1.2: Schematic of protein phosphorylation by protein kinases 
Both LRRK2 and PINK1 are protein kinases which catalyse the phosphorylation of target proteins through 
the addition of a phosphate group onto side chains of one of three amino acids (Serine, Threonine, 
Tyrosine). This process can be reversed by a separate group of enzymes known as phosphatases. 
Protein phosphorylation is a crucial cellular event leading to downstream signalling pathway activation 


















Autosomal dominant PD (late onset) 
PARK1/4 4q22.1 alpha synuclein (α-Syn) SNCA (163890) Early-onset, 
late-onset* 
PARK8 12q12 Leucine rich repeat kinase 2 LRRK2 (609007) Late-onset 
PARK17 16q11.2 VPS35, retromer complex 
component 
VPS35 (601501) Late-onset 
Autosomal recessive PD (early onset) 
PARK2 6q26 Parkin RBR E3 ubiquitin 
protein ligase (Parkin) 
PRKN (602544) Early-onset 
PARK6 1p36 PTEN induced putative kinase 
1  
PINK1 (608309) Early-onset 
PARK7 1p36.23 Parkinsonism associated 
deglycase 
PARK7 (602533) Early-onset 
PARK19 1p31.3 DnaJ heat shock protein 
family (Hsp40) member C6 
DNAJC6 (608375) Early-onset 
Autosomal recessive PD (complex genetic forms) 
PARK9 1p36.13 ATPase 13A2 ATP13A2 (610513) Early-onset 
PARK14 22q13.1 Phospholipase A2 group VI PLA2G6 (603604) Early-onset 
PARK15 22q12.3 F-box protein 7 FBXO7 (605648) Early-onset 
PARK20 21q22.1 Synaptojanin 1 SYNJ1 (604297) Early-onset 
PARK23 15q22.2 Vacuolar protein sorting 13 
homolog C 
VPS13C (608879) Early-onset 
PD Risk loci  
PARK10 1p32 Parkinson disease 10 PARK10  Late-onset 
PARK12 Xq21-q25 Parkinson disease 12 PARK12  Late-onset 
PARK16 1q32 Parkinson disease 16 PARK16  Late-onset 
Loci with current unconfirmed relationship to PD (thought to be autosomal dominant) 
PARK3 2p13 Parkinson disease 3 PARK3 (Unclear) Late-onset 
PARK5 4p13 Ubiquitin C-terminal hydrolase 
L1 
UCHL1 (191342) Early-onset, 
late-onset* 
PARK11 2q37.1 GRB10 interacting GYF 
protein 2 
GIGYF2 (612003) Late-onset 
PARK13 2p13.1 HtrA serine peptidase 2 HTRA2 (606441) Late-onset, 
early-onset* 
PARK18 3q27.1 Eukaryotic translation initiation 
factor 4 gamma 1 
EIF4G1 (600495) Late-onset 
PARK21 20p13 Transmembrane protein 230 TMEM230(617019) Late-onset, 
early-onset* 
PARK22 7p11.2 Coiled-coil-helix-coiled-coil-
helix domain containing 2 
CHCHD2 (616244) Late-onset, 
early-onset* 
TABLE 1: Current updated list of PARK1-23. The symbol, gene locus, official gene name, gene symbol 
and disease onset according to the Human Genome Nomenclature Committee (HGNC) for all PARK1-23 
loci are displayed, separated according to mode of inheritance and complex genetic forms. 3 PARK risk loci 
and 7 PARK loci with unconfirmed relationship to PD are also included. Late-onset refers to PD onset >50 
years, and early-onset <50 years. *Indicates few cases in which alternate disease onset has been recorded. 
Highlighted genes (LRRK2 and PINK1). indicate the two genes of focus within the work in this thesis.  




1.2 LRRK2  
 
Missense mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, within the PARK8 locus 
(Table 1), were found to cause PD by two independent studies in 200415,19. Currently, LRRK2 
mutations comprise the main genetic cause of PD20, and are dominantly inherited in familial 
PD patients, or appear sporadically. In particular, G2019S is the most common LRRK2 
mutation, accounting for 4% of familial and 1-2% of sporadic PD cases worldwide21,22. Notably, 
G2019S prevalence varies with ethnic background, and is particularly high within individuals 
of Ashkenazi Jewish (29% familial, 10% sporadic PD) and North African Berbers ancestry 
(40% familial and 30% sporadic PD)23. GWAS studies have also revealed that risk of 
sporadic PD is moderately increased by common protein-coding and non-protein coding 
variants at the LRRK2 locus24.  
Clinically, the phenotype of PD patients with LRRK2 mutations closely resembles those with 
sporadic PD (late-onset, tremor dominant), however differs by certain non-motor features such 
as improved smell, reduced frequency sleep behaviour disorder (RBD), and several atypical 
features such as dementia25. Different LRRK2 mutations can also produce varying 
neuropathology with and without Lewy bodies, as well as with hyperphosphorylated tau or 
ubiquitin-inclusions26. Of the G2019S mutation, Lewy bodies have been observed in most 
post-mortem samples27.  
1.2.1 LRRK2 protein structure 
The LRRK2 gene encodes a large (2527-amino acid) multi-domain protein, containing two 
enzymatic regions at its core; a Ras-of-complex (ROC) GTPase domain ending with a C-
terminal of Roc (COR) spacer domain, and a serine/threonine (Ser/Thr) kinase domain28. 
Several protein-protein interaction domains surround this enzymatic core, including a leucine-
rich-repeat (LRR) region (N-terminus), an ankyrin-like repeat region (ANK), an Armadillo 
repeat region, and a WD40 domain (C-terminus)  (Figure 1.3)22.   
LRRK2 is auto-phosphorylated at Ser1292, which resides between the LRR and GTPase 
domains, and is also phosphorylated constitutively at a cluster of serine residues (Ser910, 
Ser935, Ser955 and Ser973), which reside in a non-catalytic region between the ANK domain 
and LRR region29 (Figure 1.3). Phosphorylation of Ser910 and Ser935 sites regulate 14-3-3 
binding and LRRK2 cytosolic localisation30. Use of several diverse LRRK2 kinase inhibitors, 
such as MLi2, as well as several PD mutations in the enzymatic core of LRRK2, cause 
dephosphorylation of these sites29. Previous work has identified protein phosphatase 1 (PP1) 
as a phosphatase behind LRRK2 dephosphorylation of its serine resiudes31. However, it is still 
unclear how LRRK2 kinase activity itself influences phosphorylation of these sites.  
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The most common confirmed LRRK2 mutations cluster within the enzymatic core of LRRK2; 
R1441C/G/H and N1437H (GTPase ROC domain); Y1699C (COR domain); G2019S and 
I2020T (kinase domain)21 (Figure 1.3). Regardless of mutation position, all pathogenic 
mutations cause an increase in LRRK2 kinase activity32, thus associating kinase activity with 
PD pathogenicity. Furthermore, there is clear communication between both GTPase and 
kinase domains, given that mutations within the GTPase ROC domain of LRRK2 increase 
kinase activity by 4-fold, compared a 2-fold increase by kinase domain mutations 
themselves22. Therefore, LRRK2 represents an attractive therapeutic target for PD, in which 
LRRK2 kinase inhibitors are being developed and tested by several pharmaceutical and 
biotechnological companies for their use as potential novel PD treatments22.  
FIGURE 1.3 
FIGURE 1.3: Schematic of LRRK2 protein domains, confirmed pathogenic mutations, and 
phosphorylation of its Rab substrates following kinase activation.  
LRRK2 is a large multi-domain protein containing several protein-protein interaction domains surrounding 
a double enzymatic core; consisting of a GTPase ROC domain ending with a COR domain, and a 
serine/threonine (Ser/Thr) kinase domain. All 7 pathogenic confirmed LRRK2 mutations cluster within all 3 
domains of the double enzymatic core, with G2019S, located within the kinase domain, being the most 
common LRRK2 mutation. In addition, the serine sites of LRRK2 (Ser910, Ser935, Ser955, Ser973), are 
depicted between the ANK and LRR LRRK2 domains. LRRK2 phosphorylates a subgroup of Rab 
GTPases, of which endogenous phosphorylation for 10 Rab GTPases (orange) have been confirmed, 
whilst 3 (purple) are possibly phosphorylated32,33. Rab10 is phosphorylated at a highly conserved Thr73 
residue within the effector binding region switch II domain, whereby its crystal structure is shown in more 
detail. In a predicted model of LRRK2 activation, Rab29 binds to the ANK domain of LRRK2, and acts as 
an upstream master regulator by recruiting LRRK2 to the trans-Golgi network36.  
Original image, based upon published findings in Steger, M, et al (2017) 
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1.2.2 LRRK2 phosphorylation of Rab proteins 
Important work within the Alessi lab revealed that LRRK2 directly phosphorylates a subset of 
14 Rab GTPases, including Rab8A, Rab10 and Rab29/Rab7L1, which are its first validated 
physiological substrates32,33 (Figure 1.3). This phosphorylation occurs on a conserved Ser/Thr 
residue located within the effector binding switch-II region of their GTPase domains (Thr72 in 
Rab8A and Thr73 in Rab10)33,34. Recent work revealed that Rab7L1/Rab29 also functions as 
an upstream master regulator of LRRK235. In a predicted model of LRRK2 activation, Rab29 
binds to the ANK domain of LRRK2 and recruits it to the trans-Golgi network, which greatly 
stimulates its kinase activity36. Moreover, pathogenic LRRK2 mutants including R1441G/C 
and Y1699C are preferentially activated by Rab29 in comparison to wild-type LRRK236, 
providing further association between increased LRRK2 kinase activity and PD pathogenesis.  
Rab GTPases (~70 Rabs within humans) constitute the largest branch of the Ras superfamily, 
and are critical regulators of intracellular trafficking within eukaryotic cells37. They cyclically 
switch between inactive (GDP-bound) or active (GTP-bound) states, which are respectively 
activated by Rab guanine nucleotide exchange factors (GEFs), or inactivated through the 
hydrolysis of bound GTP by GTPase activating proteins (GAPs)38. Active GTP-bound Rabs 
associate with membranes, where they interact with a carefully orchestrated downstream 
sequence of Rab effectors (e.g. tethering factors, molecular motors), which facilitate induction 
of diverse pathways; including vesicle formation, movement, docking and membrane fusion38.  
LRRK2 mediated phosphorylation of Rab isoforms decreases their interaction with other 
known regulatory proteins or exchange factors that promote their activation and insertion into 
target membranes, such as guanosine nucleotide dissociation inhibitors (GDI); GDI1/233. 
However, LRRK2 phosphorylated forms of Rab isoforms (Rab8A, 10, 12) are able to interact 
with other effector proteins termed RILPL1 and RILPL2, which are regulators of primary 
ciliogenesis32. In the context of PD, pathogenic LRRK2 mutations located within the GTPase 
(R1441G/C) and COR (Y1C99C) domains, as well as the kinase domain (G2019S/I2020T), 
have shown to markedly enhance Rab8A and Rab10 isoform phosphorylation in vivo39, 
indicating an important role of these proteins and their downstream signalling pathways in PD 
pathogenesis.  
1.2.3 LRRK2 role during infection and inflammation   
Whilst the physiological role(s) of LRRK2 are still being uncovered, a growing amount of 
evidence points to its involvement during infection and inflammation40,41. Indeed, LRRK2 is 
part of the family of receptor interacting protein kinases (RIPK 1-7), of which different members 
play key roles in the inflammatory response to infection and apoptosis of infected cells42. 
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Supportively, whilst LRRK2 is ubiquitously expressed, its expression is significantly elevated 
within cells of the innate and adaptive immune system43, as well as in glial cells. LRRK2 
expression is further increased by multiple pro-inflammatory signals such as 
lipopolysaccharide (LPS) and interferon-γ (IFN-γ)43,44, and is also increased in the immune 
cells of PD patients41. Mutations in LRRK2 have also been associated with several 
inflammatory diseases, including leprosy45, Crohn’s disease46, SLE47, and cancer48. Thus, 
LRRK2 appears to lie at a unique nexus of neurodegeneration and inflammation. 
Mechanistically, several studies have aimed to understand how LRRK2 is activated or 
modulated in response to infection or inflammation. Notably, previous work within the Alessi 
lab found a key connection between Toll-like receptor (TLR) activation and LRRK2 
phosphorylation within mouse bone marrow derived macrophages (BMDMs)49. TLRs have a 
vital role in recognising specific pathogen-associated molecular patterns (PAMPs) present on 
invading pathogens, which lead to the induction of downstream intracellular signalling 
pathways responsible for inflammatory immune responses50. Specifically, activation of TLR’s 
1,2,5,6,7,8 and 9 signals through the MyD88-dependent pathway, which promotes TRAF6-
dependent activation of the TAK1 kinase. Subsequently, TAK1 phosphorylates and promotes 
the activation of “canonical” IKKα and IKKβ kinases, which induce the transcription of NFκB 
dependent genes, including TNFα and IL-6, that are key for the inflammatory response. In 
addition, “non-canonical” TBK1 and IKKε kinases are also activated by the MyD88 pathway, 
which have a negative regulatory effect on “canonical” IKK activation. TLR3 activation leads 
to stimulation of the MyD88-independent pathway (TRIF), leading to downstream activation of 
“non-canonical” IKK kinases, whilst TLR4 activation uniquely signals through both MyD88-
dependent and independent pathways. Figure 1.4 illustrates a summary of both TLR-
activated immune signalling pathways, and the key findings from the Alessi lab49. 
Specifically, the experiments performed within the Alessi lab revealed that activating several 
TLRs with various MyD88-dependent pathway agonists in mouse BMDMs led to increased 
LRRK2 phosphorylation at several serine residues, including Ser910, Ser935 and Ser95549. 
This phosphorylation was found to be controlled by both “canonical” IKKα and IKKβ, and “non-
canonical” (TBK1 and IKKε) kinases, whereby a combination of pharmacological inhibitors 
against both sets of kinases prevented TLR-mediated LRRK2 phosphorylation49 (Figure 1.4 
and Figure 1.5). It is still not established however what the role of TLR-mediated LRRK2 
phosphorylation is on macrophage immune response, or how this phosphorylation affects 
LRRK2 cellular kinase activity. Indeed, the authors revealed that LRRK2 KO macrophages 
still possessed a normal pro-inflammatory cytokine secretion in response to TLR2 or TLR4 
stimulation49, suggesting that LRRK2 phosphorylation in response to TLR signalling may not 















FIGURE 1.5: Immunoblot from published data (Dzamko et al., 2012) 
Immunoblot analysis demonstrating that activation of the MyD88-dependent pathway by TLR 
agonists PAM3CSK4 (1µg/ml) and Zymosan (200µg/ml) in wild-type BMDMs led to LRRK2 
phosphorylation at Ser935. Significantly, Ser935 phosphorylation was abolished only through 
combination of MRT67307 and Oxozeaenol inhibitors, which inhibit TBK1/ IKKε and TAK1 kinases 
respectively, thus demonstrating that both sets of kinases are needed for LRRK2 Ser935 
phosphorylation.  
 
FIGURE 1.4: Schematic of 
activation of Toll-like 
receptors (TLRs) by 
pathogen associated 
molecular patterns 
(PAMPs) in mouse BMDMs, 
based on published work 
from Dzamko et al., 2012.  
Downstream activation of 
both ‘canonical’ and ‘non-
canonical’ IKK related 
kinases following use of 
MyD88-dependent agonists 
in mouse BMDMs was 
shown to phosphorylate 
LRRK2 at serine sites 





Several studies have also shed insight into the activation and specific response of LRRK2 
upon cellular infection of macrophages with different pathogens. During S. Typhimurium 
infection in mice, LRRK2 co-localises with infected macrophages and helps clear the 
infection51, and is also required for mucosal immunity against Listeria monocytogenes in 
another mouse model52. In contrast, during M. Tuberculosis (M. Tb) infection, LRRK2 
negatively regulates phagosome maturation in both human and mouse macrophages, 
reducing M. Tb degradation by lysosomes and hence supporting its replication53. Therefore, 
the specific role of LRRK2 during macrophage infection intriguingly appears to be either 
beneficial or deleterious to the host response depending on the pathogen and cell host in 
question. 
 
1.3 Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic bacterium, 
ubiquitously found in soil and ground water. Its large and hypermutable genome (~5500 
genes) enables colonization and survival within a diverse range of conditions and species, 
including humans, where it can infect several sites of the body including the respiratory tract, 
urinary tract, eyes, and skin54. Several hundred strains of P. aeruginosa have been 
characterized, of which the common reference strain is PAO1, a spontaneous resistant mutant 
of the original PAO strain, isolated from a wound from a patient in Australia in 195455.  
P. aeruginosa is traditionally regarded as an extracellular pathogen, indicating that it avoids 
phagocytosis and multiplies extracellularly. However, it has also shown signs of intracellular 
activity, including its invasion and survival inside host cells, adding to its complexity56,57. Its 
mechanism of pathogenicity is directly associated with several virulence factors, including 
structural cell-associated determinants such as lipopolysaccharide (LPS) within the outer 
membrane, pili and flagellin, as well as several extra-cellular factors, including proteases, 
exotoxins and haemolysins58 (Figure 1.6A). Both LPS and flagellin act as PAMPs, and have 
shown to activate TLR2/TLR4 and TLR5 respectively59. Importantly, P. aeruginosa utilizes the 
type III secretion system (T3SS), which expresses one or more of four known exotoxins (ExoS, 
ExoU, ExoT and ExoY)60. These exotoxins are translocated into host cells and promote 
invasion and/or intracellular trafficking through modulating interaction with epithelial cells, 
immune cells and host tissues. The T3SS itself increases inflammation and neutrophil 




1.3.1 P. aeruginosa and Cystic fibrosis (CF) 
Although healthy individuals are rarely affected by P. aeruginosa, severe infections occur in 
immunocompromised individuals, as well as those vulnerable to nosocomial hospital-acquired 
infections, including patients with burn wounds, urinary tract infections or pneumonia63. In 
particular, P. aeruginosa infection is the predominant cause of morbidity and mortality in 
individuals with cystic fibrosis (CF)64, an autosomal recessive genetic disorder caused by 
mutations within the cystic fibrosis transmembrane conductance regulator (CFTR) gene, 
located on chromosome 765. All CFTR mutations cause defective transport of chloride ions 
and water across epithelial surfaces, leading to thick and sticky mucus hyper-production within 
the respiratory, digestive and reproductive systems65 (Figure 1.6B).  
Whilst CF is clearly a multi-system disorder, the effects of mucus accumulation in the 
respiratory system are currently the best studied due to the severity of breathing problems 
experienced by individuals, as well as the notorious problem of poly-microbial airway 
colonization over their lifetime. Indeed, CF individuals frequently suffer from repeated 
respiratory tract infections punctuated by acute episodes of pulmonary ‘exacerbations’, which 
contribute to worsening inflammation and damage of their airway linings66. The prevalence of 
bacteria infecting the airways in CF varies with age. Typically, CF patients are infected with P. 
aeruginosa in early childhood (~20% <2 years), and harbor the pathogen through subsequent 
years, whereby more than 70% of CF adults are chronically infected with P. aeruginosa by 
age 2567. Some studies have revealed that whilst bacterial diversity in CF airways decreases 
as severity increases, P. aeruginosa remains as the dominant organism68. 
Several genotypic and phenotypic adaptations of P. aeruginosa are thought to explain for its 
persistence in CF, including its intrinsic resistance to several antibiotics and antiseptics69, its 
ability to form diverse hypermutable strains70, and its creation of biofilms71; where micro-
colonies of bacteria grow in a self-produced extracellular matrix. Specifically, P. aeruginosa 
strains in CF appear to convert into an exopolysaccharide alginate-producing mucoid 
phenotype over time, which is associated with an accelerated loss of pulmonary function and 
increased morbidity72. In addition, previous work revealed that novel P. aeruginosa strains 
isolated from the sputum of CF patients showed marked upregulation of several drug resistant 
proteins (MexY, MexB, MexC) and downregulation of chemotaxis and aerotaxis proteins 
(PA1561, PctA, PctB), compared to the standard PAO1 strain73. Thus, it is likely that different 
P. aeruginosa strains provide alternate mechanisms of virulence and drug-resistance required 
for survival, depending on the unique lung environment of each CF individual. As a result, CF 
patients are often isolated in their clinic appointments to minimise spread of these multi-drug 
resistant P. aeruginosa strains, for which their underlying mechanisms are still unknown. 
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FIGURE 1.6  
 
 
FIGURE 1.6: Combined schematic of (A) simplified P. aeruginosa structure, (B) CF pathobiology 
within the lung architecture 
(A) P. aeruginosa is a gram-negative rod-shaped bacterium, with specific structural characteristics 
including the flagellum, pili, lipopolysaccharide (LPS) and alginate biofilm, of which the latter forms in 
differentiated strains. Extra-cellular virulence factors, including several proteases, T3SS exotoxins and 
haemolysins are also outlined.  
(B) Illustration depicting the normal CFTR channel, which allows movement of chloride ions into the extra-
cellular space in mucus-secreting glands, contrasted with impaired chloride movement within the mutant 
CFTR channel in cystic fibrosis (CF). The airways cross-section above reveals thick mucus in CF 
individuals with mutant CFTR channels, which is responsible for the breathing problems and recurrent 
infections. 
(C) Illustration showing the clearance of P. aeruginosa from healthy individuals through effective 
phagocytosis by healthy neutrophils (top image), contrasted with the impaired P. aeruginosa clearance 
in CF individuals despite the large efflux of neutrophils. CF neutrophils appear defective, and additionally 
cause damage to the CF airways. P. aeruginosa persistence in CF individuals facilitates further strain 







1.3.2 Neutrophils, LRRK2 and P. aeruginosa 
As a general immune defence mechanism, neutrophils are key for the elimination of P. 
aeruginosa and prevention of infection in healthy individuals (Figure 1.6C), thus neutropenic 
patients have higher frequencies of P. aeruginosa infection63. Neutrophils are the most 
common type of white blood cell, and are usually the first immune cells to arrive at the site of 
inflammation. They provide essential non-specific host defence via releasing several 
proteases, reactive oxygen species (ROS) and metabolites, and can be stimulated to 
synthesise and secrete several cytokines and chemokines required for activating inflammatory 
pathways against P. aeruginosa74.  
Paradoxically, the large infiltration of neutrophils across the airway epithelium of CF patients 
during infection appears a key factor behind pulmonary exacerbations and the persistence of 
P. aeruginosa (Figure 1.6C). CF neutrophils appear to have a reduced phagocytic capacity 
and impaired function for host defense against P. aeruginosa, which is further impeded by the 
thick inflammatory environment of the CF mucus75,76. Furthermore,  proteases including 
elastase and matrix metalloproteinases (MMPs) released from neutrophil toxic granules cause 
irreversible tissue damage and structural remodeling of the CF airways, which worsens 
prognosis77. Currently, it is not known whether defects in the CFTR channel influence the 
migration or function of neutrophils78, or whether there are any other genes which may be 
involved in the excessive inflammatory response in CF. 
Interestingly, neutrophils have been reported to demonstrate a high expression level of both 
LRRK2 and Rab10 (Figure 1.7). A considerable advantage of the use of neutrophils for 
experimentation is that they can be readily isolated from human blood in around 30 minutes, 
of which isolated cells are 98-99% homogenous79. With this knowledge, the Alessi lab has 
recently employed a robust assay to interrogate LRRK2 kinase pathway activity and assess 
molecular changes within human peripheral blood neutrophils79. Crucially, this work has been 
facilitated through use of the newly developed highly specific and sensitive MJFF-pRab10 
rabbit monoclonal antibody, which detects Rab10 phosphorylated at Thr73 by LRRK239, hence 
can be used as a direct readout of LRRK2 activity. In addition, neutrophils within the sputum 
of CF patients comprise of the major cell type, and can be quickly isolated by established 
techniques. Hence, human neutrophils provide an ideal source to explore the role of LRRK2 










Abundance of LRRK2 and Rab10 within immune cells isolated from human peripheral blood, 
based on data from Immprot database (http://www.immprot.org) 
Graphical display of high numbers of protein copies per cell for of both LRRK2 and Rab10 within 
neutrophils and several types of monocytes. To obtain this data, the study used fluorescence-activated 
cell sorting (FACS) to isolate pure populations of immune cells isolated from human blood. Histone rule 
was used to estimate the protein copy numbers per cells.  
Image published as Figure 1 in Fan, Y et al., 2018 and reproduced with permission from authors.  
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1.4 PINK1 and Parkin 
 
Two other important genes linked to PD are PINK1 (PTEN-induced kinase 1; human PARK6), 
which encodes a serine/threonine protein kinase, and Parkin (human PARK2), encoding a 
ubiquitin E3 ligase (Table 1). Loss-of-function homozygous or compound heterozygous 
mutations, as well as rearrangements in these genes, are the most common causes of 
autosomal recessive early-onset PD (below age of 45)23. PD patients with either mutation have 
clinically indistinguishable phenotypes, with largely restricted nigrostriatal pathology that can 
interestingly be spared of Lewy body inclusions, in reported cases80.  
Notably, the PINK1 and Parkin enzymes respectively encoded by each gene converge on an 
evolutionarily conserved signal transduction pathway which regulates mitochondrial 
homeostasis and quality control, including the selective elimination of damaged mitochondria 
from cells through a process known as mitophagy. These findings enhanced the growing 
hypothesis that mitochondrial dysfunction is one of the key mechanisms underlying 
Parkinson’s pathogenesis7. Indeed, PD-related PINK1 mutations have shown to inhibit PINK1 
kinase activity and prevent mitophagy initiation in cells with mitochondrial damage, leading to 
reactive oxygen species accumulation and neuronal loss81. Furthermore, experiments using 
Drosophila models of PINK1 have revealed that neurodegeneration could be rescued in only 
wild-type (WT) versions of the PINK1 gene compared to kinase-inactive versions82. Thus, 
better understanding of the connection between PINK1/Parkin pathway dysfunction and 
dopaminergic neurodegeneration provides important insights into PD, and may help with 
future development of neuroprotective treatments.  
1.4.1 PINK1/Parkin signalling pathway 
Considerable work in cell culture over the last decade has helped shed light on the 
mechanisms by which the PINK1/Parkin pathway normally regulates mitochondrial 
homeostasis and mitophagy80. PINK1 is unique amongst all other kinases due to the presence 
of an N-terminal mitochondrial targeting sequence (MTS). In addition, it contains a 
transmembrane domain, and three insertional loops (Ins1-3) within its catalytic kinase 
domain83 (Figure 1.8A).  
Under basal conditions within healthy mitochondria, PINK1 is synthesised at the ribosome as 
its full-length 63kDa form. It is targeted from the cytosol to the mitochondria through its N-
terminal MTS, and is then translocated from the outer mitochondrial membrane (OMM) to the 
inner mitochondrial membrane (IMM) through the Translocase of the Outer Membrane (TOM) 
and Translocase of the Inner Membrane (TIM) complexes, respectively84. Once at the 
mitochondrial matrix, PINK1 is sequentially cleaved in two steps; first by the mitochondrial 
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processing peptidase (MPP) to its 60kDa intermediate form, and then by presenilin-associated 
rhomboid-like protein (PARL) to its 52kDa mature form85. Following cleavage, the 52kDa 
mature form is exported back into the cytosol, where it is rapidly degraded by the N-end rule 
pathway86.  
However, upon mitochondrial depolarisation or conditions of stress/damage (which can be 
induced by mitochondrial uncouplers), full-length PINK1 becomes activated and stabilised on 
the OMM of mitochondria through inhibition of its mitochondrial import and cleavage87. Herein, 
PINK1 phosphorylates ubiquitin (Ub) present on proteins within the OMM at Serine 65 (Ser 
65) (becoming ‘phospho-ubiquitin’, pUb), which stimulates recruitment of Parkin to the 
mitochondria. The subsequent binding of Parkin with phosphorylated ubiquitin molecules 
results in a conformational change that primes Parkin for its phosphorylation by PINK1 at its 
Ser65 residue within its N-terminal ubiquitin-like domain (UbI)87. Parkin Ser65 phosphorylation 
is essential for activation of Parkin E3 ligase activity88,89, which polyubiquitylates multiple 
proteins at the OMM, leading to their de novo assembly and elongation. The ubiquitin chains 
on these proteins are in turn phosphorylated by PINK1, which are then targeted for 
degradation in the lysosome. This promotes a feedforward loop amplification for the 
completion of mitophagy, thus promoting cell survival and protection against apoptosis 
(Figure 1.8B).  
Additional findings have revealed that activated PINK1 indirectly regulates phosphorylation of 
a subset of Rab proteins including Rab8A, 8B and 13 at Serine 111 (Ser111), which appears 
independent of its direct activation of Parkin E3 ligase activity (Figure 1.8B) 90. Excitingly, 
recent work has revealed that whilst Ser111 phosphorylation does not alter Rab8A structure, 
































FIGURE 1.8: PINK1 structure and pathway 
(1.8A) Human PINK1 domain architecture, showing an N-terminal mitochondrial targeting domain, a 
kinase domain containing 3 insertional loops (Ins1-3), a catalytic motif (HRD) and activation loop motifs 
(DFG, APE) and a C-terminal extension (CTE).  
(1.8B) Schematic diagram of PINK1/Parkin pathway activation following mitochondrial depolarisation. 
PINK1 is stabilised at the outer mitochondrial membrane (OMM) and prevented from degradation. Here, it 
phosphorylates Parkin and Ubiquitin at their respective Ser65 residues. This is crucial for Parkin activation, 
leading to poly-ubiquitylation of several substrates, including CISD1, Miro1 and Mfn2. These ubiquitin chains 
are subsequently phosphorylated by PINK1, contributing to the feed forward amplification of the cycle to 
complete the mitophagy process. PINK1 also indirectly regulates the phosphorylation of Rab8A at Ser111. 




1.4.2 Detecting PINK1 expression and activity in human cells  
Detection and analysis of endogenous PINK1/Parkin signalling and mitophagy in mammalian 
tissues has been challenging due to the high turnover of PINK1 under normal conditions, 
coupled with previous limitations in available antibody tools to sensitively and specifically 
detect PINK1 at its low levels. Hence, most understanding of the role and activation of PINK1 
has been derived from in vitro observations and cell culture studies using highly 
overexpressed exogenous PINK1 and/or Parkin and artificially induced mitochondrial 
depolarisation through uncoupling agents91.  
Whilst PINK1 mRNA is ubiquitously expressed in humans, its expression is highest within 
metabolically active human tissues and organs; including cardiac and skeletal muscles, the 
testes and the brain92, which is consistent with its role in mitophagy. Within the brain, higher 
PINK1 expression is observed in neuronal cells of the substantia nigra, hippocampus, and 
cerebellar Purkinje cells93. Obtaining bio-samples of these cells from living patients to 
investigate PINK1/Parkin activity provides obvious limitations. However, recent work within 
the Muqit lab provided the first direct analysis of PINK1/Parkin pathway activity in primary 
fibroblast cultures established from human skin biopsies89,94. Specifically, 3-hour treatment 
with the mitochondrial uncoupler CCCP (carbonyl cyanide 3-chlorophenylhydrazone) in 
fibroblasts derived from PD patients harbouring PINK1 mutations/Parkin Ser65N homozygous 
mutations, compared to in those from a healthy subject, abolished Parkin Ser65 
phosphorylation and activation. This was associated with a substantial reduction in CISD1 
ubiquitylation and reduced accumulation of pUb as readouts of Parkin E3 ligase activity in 
CCCP-treated Ser65N mutated fibroblasts.  
Notably, recent work within the Alessi lab promoted the suggestion to consider neutrophils as 
a key bioresource in Parkinson’s bio-repositories79. As discussed above, peripheral blood 
neutrophils can be quickly isolated from whole blood through the robust assay developed, and 
has successfully been used to measure endogenous LRRK2 activity through the highly 
sensitive and specific pRab10 antibodies employed. Using the current antibody tools available 
to interrogate PINK1/Parkin activity, it would thus be beneficial to investigate if PINK1 activity 







1.5 Project aims 
 
The first aim of my project (Project A) was to explore if I could activate LRRK2 during infection 
of immune cells with P. aeruginosa. The P. aeruginosa strains I used within this project 
included the characterised (PAO1) strain, as well as several uncharacterised strains isolated 
from the sputum of chronically infected CF patients (Strains ‘A-D’). I directly isolated 
neutrophils from human peripheral blood, as well as from sputum samples provided by P. 
aeruginosa infected CF patients. I used both human neutrophil cell types to investigate LRRK2 
activity through assessing LRRK2-dependent Rab10 phosphorylation. I also isolated, cultured 
and infected mouse bone marrow derived macrophages with P. aeruginosa strains to 
investigate the resultant impact on LRRK2 Ser935 phosphorylation, as well as for LRRK2-
dependent Rab10 phosphorylation.  
The second aim of my project (Project B) was to investigate if I could detect PINK1 in human 
peripheral blood neutrophils, following induction of mitochondrial depolarisation over several 
time courses using the mitochondrial uncoupler CCCP. I used immunoblotting and 
immunoprecipitation (IP) experiments with the PINK1 (Novus) antibody to confirm the 
detection of stabilised PINK1 in peripheral blood neutrophils. If successful, my project findings 
would indicate that peripheral blood neutrophils could be utilised as useful cell type to directly 
and quickly assess for PINK1/Parkin pathway dysfunctions in PD patients. This could promote 
future exploration into the overall role in which this pathway plays in PD pathogenesis for both 














2. CHAPTER 2 – MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents 
Signal transduction inhibitors of LRRK2 (MLi2), TBK1/IKKε (MRT67307) and TAK1 (NG25), 
as well as Protein G Sepharose beads for immuno-precipitation were provided by the MRC 
Reagents and Services, University of Dundee. Tissue culture reagents were obtained from 
Life Technologies. CCCP was obtained commercially through Sigma (#C2759), and stocks 
kept frozen at -200C.  
2.1.2 Antibodies  
Primary antibodies used include in-house antibodies produced by the MRC Reagents and 
Services, or commercially available antibodies, which are respectively listed in in Table 2.  
TABLE 2: In-house generated antibodies with the Michael J. Fox foundation (MJFF) 
and Commercial antibodies utilised within the project  
Antibodies  Identifier  Company Host 
Michael J. Fox foundation    
p(Ser935)-LRRK2  UDD2 MRC Reagents and Services  Rabbit  
Total LRRK2 (C-terminus) N241A/34 Neuromab Mouse  
p(Thr73)-Rab10  MJF-R21 Abcam  Rabbit 
Total Rab10 Clone- 605B11 Nanotools Mouse 
p-Rab8 MJF-20-25-5 Abcam Rabbit  
p(Thr71)-Rab7L1 (Rab29)  S877D (sheep 
number)  
MRC Reagents and Services Mouse  
Total Rab7  9367 Cell signalling Rabbit  
Commercial    
Total Rab8A 6975 Cell signalling Rabbit  
p-p38 MAPK 9211 Cell signalling  Rabbit  
GAPDH 2118 Cell signalling Rabbit  
Tubulin 5174 Cell signalling  Mouse 
PINK1 human BC-100-494 Novus  Rabbit  
Parkin human Sc-32282 SantaCruz Mouse  





2.2 Study participants 
2.2.1 Blood and sputum sample collection 
For experiments utilising human peripheral blood neutrophils, members of the School of Life 
Sciences at the University of Dundee kindly donated 20ml blood per experiment, which was 
collected into BD Vacutainer tubes (BD Vacutainer Haemogard Closure K2-EDTA Tubes).  
For experiments utilising sputum neutrophils, naturally expectorated sputum samples were 
obtained from CF patients who were attending clinic appointments at the Respiratory 
department of Ninewells hospital following a recent infective exacerbation. Before samples 
were collected, explanation of the project and informed consent from each patient was 
obtained, in accordance with hospital procedures. Although no formal sputum culture analysis 
was obtained from each patient at the time of sputum collection, all CF patients had confirmed 
P. aeruginosa cultures previously detected in sputum samples. No demographic or clinical 
information from CF patients was obtained and samples were kept anonymised.  
Given that healthy individuals cannot naturally produce sputum, a neutrophil sputum control 
sample was obtained from a patient with Primary Ciliary Dyskinesia (PCD). PCD is an inherited 
autosomal-recessive disorder characterised by impaired muco-ciliary clearance mechanisms 
due to abnormal ciliary beating, thus leading to copious sputum production95. Whilst no formal 
sputum culture could be obtained for this patient, the patient was not reported to be suffering 
from an infection during the time of sputum collection, nor had previous culture positive for P. 
aeruginosa infection, hence was utilised as a ‘non-infected’ control for sputum neutrophil 
preliminary assessment. As above, a neutrophil blood control was obtained from a healthy 
blood donor at the School of Life Sciences. 
2.3 Cell isolation 
2.3.1 Peripheral blood neutrophil isolation 
The peripheral blood neutrophil isolation procedure was commenced within 30 minutes of 
blood collection, through immune-magnetic negative isolation with the Direct Human 
Neutrophil Isolation Kit (STEMCELL Technologies, #19666), which had been previously 
purchased for work within the Alessi lab. The established neutrophil isolation Dundee protocol 
is summarised below79, with Figure 2.1 illustrating the main mechanism behind neutrophil 
isolation.  
20ml freshly collected blood samples from each donor was transferred into individual 50ml 
falcon tubes, and 1ml of “Isolation cocktail” from the Neutrophil Isolation Kit was added to each 
tube. “Rapid-Spheres magnetic beads” from the isolation kit were vortexed for 30 seconds and 
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1ml added to the blood sample, mixed by gently inverting the blood tube, and left to incubate 
at room temperature for 5 minutes. “EDTA Stock Solution 2” (1mM EDTA-PBS solution) was 
added to each tube to the 50ml mark, and mixed by gently pipetting up and down. Each blood 
tube was carefully placed into an EasySep magnet (STEMCELL Technologies, #18002), and 
left for 10 minutes at room temperature. The enriched cell suspension containing neutrophils 
in the middle of each falcon tube was pipetted using a 20ml pipette and transferred into a new 
50ml falcon tube, with care taken not to touch the sides of the tube in contact with the magnet. 
Around 10ml of red blood cell suspension was left at the bottom of each tube. 1ml of Rapid-
Spheres magnetic beads were added again to the new enriched cell suspension, mixed gently 
through inversion, and left to incubate at room temperature for a further 5 minutes. Each tube 
was placed again into the magnet and left for 5 minutes at room temperature. The enriched 
cell suspension was taken up by pipette and transferred into a new 50ml falcon tube, which 
was placed immediately into the magnet for a final time, and left for 10 minutes. The final 
suspension contained pure neutrophils, which was transferred into a new 50ml falcon tube. 
Each tube was topped up with 1mM EDTA stock solution 2 to a final volume of 40ml, gently 
mixed, and centrifuged at 335xg for 5 minutes. Immediately after centrifugation, the 
supernatant from each tube was carefully discarded to leave the neutrophil pellet. Neutrophil 
pellets were resuspended in 10ml of RPMI medium at room temperature by gently pipetting 




FIGURE 2.1: Schematic of key mechanisms behind immune-magnetic negative isolation using 
the EasySep Direct Human Neutrophil Isolation Kit to obtain a pure enriched fraction of 
peripheral blood neutrophils.  




2.3.2 Sputum neutrophil isolation 
Sputum neutrophil isolation was commenced within 2 hours of sputum collection, and was 
performed according to the protocol advised by Professor James Chalmers, Ninewells 
Hospital. 1g of each freshly expectorated sputum sample was weighed, transferred into 15ml 
sterile centrifuge tube, and resuspended in 8ml of PBS. Each resuspended sputum sample 
was agitated on ice for 15 minutes, prior to centrifugation at 335 x g for 10 minutes at 40C. 
After centrifugation, 4ml of PBS supernatant was removed from each tube to leave sputum 
samples dissolved in the remaining supernatant. Sputolysin (Dithiothreitol, Concentration 9-
11mg/Ml, #578517) was provided by Professor James Chalmers, and made to a 1:5 dilution 
with sterile water. 4ml of Sputolysin dilution was added to each sputum sample, vortexed for 
2 minutes, and agitated for 15 minutes at 40C. Each sputum sample was filtered through a 
48mm nylon gauze pre-dampened in PBS, into a second tube. Sputum filtrates were 
centrifuged at 335 x g for 5 mins, supernatants discarded, and sputum pellets resuspended in 
10ml of RPMI medium at room temperature.  
2.3.3 Bone Marrow Derived Mouse Macrophages (BMDM) isolation 
Preparation of the culture medium used for BMDM growth included the addition of 5ml of stock 
Penicillin/Streptomycin (P/S) and L-glutamine to a 500ml bottle of DMEM. 150ml of DMEM + 
P/S+ L-glutamine solution was removed and replaced with 50ml of heat-inactivated fetal 
bovine serum (FBS) and 100ml of L929-cell conditioned medium. 
Bone marrow precursor cells were isolated from sacrificed mouse femurs and tibiae under 
sterile conditions, and red cells removed using ammonium chloride lysis buffer. Bone marrow 
cells were flushed with PBS, diluted in pre-prepared BMDM culture media at 106 cells/ml, 
plated into normal tissue culture (TC) 10cm Petri dishes (10ml each), and placed within an 
incubator set at 37°C. Primary macrophages remained within the supernatant, whilst resident 
macrophages and fibroblasts adhered to the TC plastic. On Day 3, suspended cells were 
transferred into 10cm bacteriological dishes and returned to the at 37°C incubator. On Day 6, 
5ml bone marrow growth medium was added to each 10cm dish. By Day 8, bone marrow cells 
had finished proliferating and were ready to be harvested, and were re-plated at 1x106 per well 
(6 well plate), for which they were viable to use till Day 12. 24 hours before experimentation 
with P. aeruginosa strains, current medium was replaced with bone marrow growth medium 
without P/S, to ensure P. aeruginosa growth was not impaired. In some initial experiments, 
the impact of using original medium with P/S on P. aeruginosa growth was tested.  
Rab29 knockout (KO) mouse BMDM cells were provided by Alexia Kalogeropulou from the 
Alessi lab, and cells cultured as described above.  
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2.3.4 HEK293 and HeLa cell culture 
HEK293 FLP In T-Rex PINK1 knockout cells and PINK1 knockout with stably re-expressed 
PINK1-3X FLAG cells, and HeLa Wild-Type (WT)/PINK1 Knockout (KO) cells were gifted by 
Dr Richard Youle to the lab, which were used for control experiments. Both cell types were 
cultured in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% FBS, 2 
mM L-glutamine and P/S. Cells were plated in 10cm tissue culture dishes, and kept at 37 °C.  
2.4 Inhibitor treatments 
2.4.1 MLi2 and kinase inhibitor treatments 
Peripheral blood neutrophils and sputum neutrophils resuspended in RPMI medium were 
divided equally into two tubes labelled ‘MLi2’ and ‘DMSO’, and respectively treated for 30 
minutes with 200nM MLi-2, a potent and highly selective LRRK2 inhibitor, or DMSO. Each 
tube was inverted every 10 minutes during the 30 minutes. Following 30 minutes incubation, 
sputum neutrophils were immediately lysed according to the procedure described below in 
A.2.5.1, whilst peripheral blood neutrophils were utilised for P. aeruginosa experiments, and 
were thus subsequently plated into sterile tissue culture 60mm dishes (~5 x106 neutrophils per 
dish).  
BMDMs were treated with 200nM MLi2 (LRRK2) inhibitor, or DMSO as a control, for 1 hour 
before infection with P. aeruginosa. In later experiments, BMDMs were treated with either 2µM 
NG25 (TAK1 inhibitor), 2µM MRT67307 (TBK1/IKKε inhibitor), 200nM MLi2, or DMSO alone 
or specified combinations for 1 hour before P. aeruginosa infection. 
2.4.2 CCCP treatments  
Peripheral blood neutrophils were stimulated with 10µM CCCP for 3,6,9, 12 and 20-hour 
durations, and left to incubate at 37 °C during treatments.  
HEK293 cells were first treated with 0.1ug/ml Doxycycline for 24 hours, followed by 3-hour 
treatment of 10µM CCCP. HeLa cells were directly stimulated with 10µM CCCP, or 10µM 







2.5 P. aeruginosa infection experiments  
 
Of note, the procedures outlined in 2.5.1-2.5.3 were carried out as part of a shared 
collaborative project with Prosenjit Pal, a member of the Alessi lab. 
2.5.1 P. aeruginosa strains and media 
P. aeruginosa laboratory strain PAO1 (characterised) and clinical isolate (uncharacterised) 
strains ‘A-D’ were provided by Professor James Chalmers, Ninewells Hospital. Clinical isolate 
strains were obtained from sputum samples of Cystic Fibrosis (CF) patients with chronic P. 
aeruginosa infection in the NHS Microbiology department of Ninewells hospital. Strains were 
stored on beads and kept frozen -80 °C. 
Luria Bertani (LB) media and plates were supplied by the Media Kitchen of the University of 
Dundee. 
2.5.2 P. aeruginosa plating, serial dilution protocol 
P. aeruginosa cultures were prepared 1 day prior to performing infection experiments. In brief, 
one bead from each P. aeruginosa strain was inoculated into LB media without antibiotics, 
and grown overnight (16 hours) in the 37°C incubator on a shaker at 200rpm. The next day, 
100µl from each overnight culture was added into 900µl 50% glycerol within Eppendorf tubes 
to make a stock solution, and were vortexed. Serial dilutions were performed from stock 
solutions; 100µl of stock solution was added into 900µl 50% glycerol stock within an 
Eppendorf, vortexed (10-1), and the procedure repeated up to 10-8 dilution. 20µl of serial 
dilutions 10-5 -10-8 were streaked onto individual sterile agar plates without antibiotics using 
sterile applicator sticks, and left to incubate at 37°C for 16 hours. All serial dilutions, including 
the original stock solution, were left within the fridge at 5°C.  
The next day, the number of bacterial colonies grown on each plate were counted and 
estimations of the bacterial concentration/ml within the original stock calculated for same day 
use in peripheral blood neutrophil/ mouse BMDM infection experiments.  
2.5.3 P. aeruginosa infection procedure 
Infection experiments were conducted under CL2 conditions in the molecular microbiology 
department (prior approval obtained). Peripheral blood neutrophils pre-treated for 30 minutes 
with MLi2/DMSO were infected with P. aeruginosa PAO1 and clinical isolates strains at a 
calculated multiplicity of infection (MOI) factor of 10. BMDMs pre-treated with 1 hour of 
MLi2/DMSO or NG25/MRT67307/MLi2/DMSO inhibitor treatments were infected with P. 
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aeruginosa PAO1 initially at MOI 10 or 50, and then future experiments utilising either PAO1 
or P. aeruginosa clinical isolate strain ‘A’ at MOI 10. Given that all P. aeruginosa infection 
durations were 0, 0.5, 1, 2 or 4 hour treatments, cells were treated at staggered timepoints 
and lysed together. In between infections, all cells were kept incubated at 37°C. 
2.6 Cell lysis 
2.6.1 Peripheral blood and sputum neutrophil cell lysis 
Lysis buffer used contained 50 mM Tris-HCL pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium 
orthovanadate, 10 mM β-glycerophosphate, 50 mM NAF, 5 mM sodium pyrophosphate, 0.27 
M sucrose, 0.1% (v/v) 2-mercaptoethanol and 1% (v/v) Triton X-100. Importantly, lysis buffer 
used for neutrophil experiments also contained DIFP, a toxic protease inhibitor, which was 
needed to suppress the intrinsic serine protease activity that is high in neutrophils79. Pre-
prepared lysis buffer aliquots were kept frozen at -800C, and defrosted on ice immediately 
before use.  
Slightly different lysis procedures were required for neutrophil and BMDMs in order to 
maximise cell collection, given that neutrophils do not adhere to TC plate surfaces compared 
to BMDMs. Hence, peripheral blood neutrophils from each plate were gently scraped off and 
transferred into a separate 15ml falcon tube using a pipette, to ensure that all neutrophils 
collected remained within the media. All tubes were centrifuged at 335xg for 5 minutes at room 
temperature, and supernatants immediately discarded. 100µl chilled lysis buffer was added to 
each neutrophil pellet, resuspended, and transferred to Eppendorf tubes. Neutrophil pellets 
were left to lyse on ice for 10 minutes, and lysates clarified by centrifugation at 800g for 15 
minutes at 40C. Supernatants were transferred into labelled Eppendorf tubes and used for 
protein quantification by Bradford assay (Thermo Scientific), and samples prepared for 
immunoblotting. Excess lysate was snap-frozen and stored at −80°C for future work.  
For lysis of sputum neutrophils, the same procedure beginning from the centrifugation of 
neutrophils within tubes was carried out following completion of 30-minute MLi2/DMSO 
treatment. 
For lysis of BMDMs, culture media was aspirated from each dish to leave the cells adhered to 
the bottom of the plate. BMDMs were gently washed with 1ml of phosphate-buffered saline, 
prior to addition of the lysis buffer. Cells were lysed on ice in standard lysis buffer without 




2.7 Quantitative Immunoblot (IB) analysis 
 
Cell lysates were mixed with 4x SDS-PAGE loading buffer to a final protein concentration of 
1µg/ul and heated at 90 degrees for 5 minutes. Samples (10-40µg) were loaded onto 
commercial 4-12% Bis-Tris gels, electrophoresed at 130V for 2 hours and electrophorectically 
transferred onto nitrocellulose membrane at for 90V for 90 minutes.  
Transferred membrane was blocked with 5% (w/v) skim milk powder dissolved in TBST for 1 
hour, and then cropped at relevant molecular weight levels for overnight incubation at 4 
degrees with the relevant primary antibodies, which were all diluted in 2% BSA in TBST at a 
final concentration of 1µg/ml for each antibody (Table 2). The following day, membranes were 
washed three times with TBST for 10 minutes each, followed by 1-hour secondary antibody 
incubation at room temperature (goat anti-mouse IRDye 680LT multiplexed with goat anti-
rabbit IRDye 800CW secondary antibodies diluted in TBST at a 1:10,000 dilution). Membranes 
were washed again with TBST 3 times for 10 minutes each, imaged using infrared fluorescent 
detection with the Odyssey CLx Licor imaging system, and quantified with the Image Studio 
Software. For parts of Project B requiring higher sensitivity for detection of PINK1, 
membranes were developed using ECL. 
2.8 PINK1 Immuno-precipitation (IP) experiments 
 
For immunoprecipitation (IP) of PINK1 from control cell lysates and peripheral blood 
neutrophils, 1mg of whole-cell lysate was incubated overnight at 4°C with 10µg of Protein G 
Sepharose pre-bound to 10µg PINK1 (in-house S085D, 3rd bleed) antibody. The next day, 
immunoprecipitations were washed 3 times with high salt (150mM NaCl) lysis buffer, then 
once with 50mM Tris-HCl Ph 7.5, and eluted by resuspending in 25µl of 2x SDS sample buffer. 
Samples were agitated at 50°C within a Thermo-Mixer for 20 minutes, followed by 5 minutes 
at 75°C, before transferral to Spin X centrifuge filters. 75% of IP sample was loaded into 8% 
Bis-Tris commercial gels, and subjected subsequent Western blot procedure as described 








3. CHAPTER 3 – PROJECT A RESULTS 
3.1 Investigating LRRK2 activity following P. aeruginosa infection in neutrophils 
For Project A, my aim was to investigate the effect of P. aeruginosa infection in immune cells 
on LRRK2 activity, using Rab10 phosphorylation at Thr73 (pThr73-Rab10) detected through 
the highly sensitive MJFF-pRab10 antibody as an indirect readout. Human neutrophils have 
high expression of LRRK2 and Rab10, (Figure 1.5), hence I first investigated the impact of P. 
aeruginosa infection on peripheral blood neutrophils over a 4-hour time-course. Specifically, I 
directly isolated neutrophils from the blood of healthy donors, and pre-treated them for 30 
minutes with/without MLi2 prior P. aeruginosa infection, in order to confirm LRRK2-dependent 
pRab10 findings. Given that P. aeruginosa strains have shown key phenotypic and genotypic 
differences, I also investigated for any differences in LRRK2 activation by P. aeruginosa 
strains. For this, I utilised both the standard characterised PAO1 strain, as well as 4 
uncharacterised clinical isolate strains obtained from sputum samples of chronically infected 
CF patients with P. aeruginosa. Of note, work conducted and presented within Figures 3.1-
3.3 were part of a shared project with Prosenjit Pal, a member of the Alessi lab. 
3.1.1 Increased LRRK2-mediated Rab10 phosphorylation following P. aeruginosa 
infection within human peripheral blood neutrophils  
The results in Figure 3.1 demonstrate a progressive increase in pThr73-Rab10 levels within 
peripheral blood neutrophils during PAO1 infection over a 4-hour time-course. The MLi2 
dependent elimination of pThr73-Rab10 signal, as well as p.S935-LRRK2 signal, confirmed 
that the phosphorylation observed was LRRK2-dependent. Interestingly, at the 4-hour 
infection time-point, a band-shift was observed in total Rab10, as well as in several other Rab 
proteins including Rab8A, 7, and p-Rab8 (MJFF-20-25-2). The band-shifts were also present 
with MLi2 treatment, therefore were independent of LRRK2 activity. Hence, the shifts could 
be indicative of post-translation modifications (PTMs) of Rab proteins by PAO1, of which future 
work is required to further investigate this possibility.  
Activation of the p38 mitogen activated protein kinase (MAPK) signalling pathway results in 
phosphorylation of MAPK and nuclear translocation, and occurs in response to several cellular 
stresses96. Thus, levels of phosphorylated p38 (p.p38) were used as a marker of cellular 
response to infection. In Figure 3.1, an increase in p.p38 levels was observed in peripheral 
blood neutrophils infected with PAO1 at 1-2 hours duration, indicating a response to infection. 
The decreased p.p38 levels observed by 4 hours may have been due to protein degradation 
at longer infection time-points. More accurate assessment of p38 MAPK activation in response 
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to P. aeruginosa infection would require comparison of p.p38 against total levels of p38, which 
was not performed in this work.  
Figures 3.2 and 3.3 demonstrate results of peripheral blood neutrophils infected with several 
uncharacterised P. aeruginosa clinical isolate strains (Strains A-D), which were obtained from 
sputum samples of chronically infected CF patients. As for Figure 3.1, the results reveal an 
increase in LRRK2-dependent Rab10 phosphorylation over the time-course of each P. 
aeruginosa clinical isolate infection, although quantitative analysis revealed variability in the 
rate and amount of Rab10 phosphorylation between strains and between donors. For 
example, whilst the pThr73-Rab10/Total Rab10 ratio is highest at 4 hours in both donors for 
Strains A and C, Strain D showed a reduced ratio in Donor 1 at 4 hours of infection. 
Conversely, 4 hours of infection with Strain B resulted in considerable neutrophil death, 
revealed through the reduced GAPDH signal in both donors. 
Strain C appeared to show a similar time-course of increased Rab10 phosphorylation in 
neutrophils to the PAO1 strain (Figure 3.1), possibly suggesting similar properties of the 
strains. However, the band-shift of several Rab proteins at 4 hours of infection with PAO1 
(Figure 3.1) was not observed with any of the clinical isolate strains, which may suggest 
specific differences of PAO1 strain interaction with Rab proteins. Explanations for the reasons 
behind P. aeruginosa strain differences, as well as future methods to better interrogate the 
impact of these differences on LRRK2 biology, is explored within the discussion (5.1.1) 
In all experiments (Figures 3.1-3.3), use of MLi2 led to LRRK2 Ser935 dephosphorylation, 
confirming the ability of LRRK2 kinase inhibitors to control LRRK2 phosphorylation. On 
analysis of total LRRK2, whilst the molecular weight of full-length LRRK2 resides around 
250kDa, use of the LRRK2 antibody recognising the C-terminal domain of LRRK2 in Figures 
3.2 and 3.3 revealed a strong band above 150kDa (~170kDa) in both Donor 1 and Donor 2, 
corresponding to an N-terminally truncated form of LRRK2. Previous work on peripheral blood 
neutrophils using this antibody have similarly reported the presence of this truncated LRRK2 
170kDa species, which showed higher abundance compared to the full-length 250kDa form79. 
This truncated form is thought to result from proteolysis of LRRK2 in neutrophils, which have 






















FIGURE 3.1: Increased LRRK2-mediated Rab10 phosphorylation following P. aeruginosa PA01 
infection of human peripheral blood neutrophils  
(Top) Immunoblot analysis of peripheral blood neutrophils infected with characterised PAO1 P. aeruginosa 
strain. Peripheral blood neutrophils were isolated from whole blood samples from healthy donors. 
Neutrophils were pre-treated with +/- 200nM MLi2 for 30 minutes, prior to infection with PAO1 over a time 
course of 0-4 hours (MOI 10). Membranes were probed with indicated antibodies (1µg/ml antibody) within 
Table 2; pT73 Rab-10 and Total Rab10 to investigate LRRK2 activity, as well as additional antibodies for 
the following Rab proteins: Rab 8A, Rab7 (total), p-Rab8 (MJFF-20-25-2). MLi2 treatment was verified by 
immunoblotting with pS935-LRRK2 antibody, and P. aeruginosa infection verified through probing against 
p.p38. GAPDH was used as an internal loading control. (Bottom) Quantification of immunoblots analysed 









FIGURE 3.2: Increased LRRK2-mediated Rab10 phosphorylation following infection of human peripheral blood neutrophils (Donor 1) with P. aeruginosa 
clinical isolates (uncharacterised Strains ‘A-D’)  
(Top) MLi2 treatment and infection time-courses in peripheral blood neutrophils isolated from Donor 1 were repeated as described above in legend for Figure 3.1. 
Each P. aeruginosa strain (A-D) was obtained from the sputum of different chronically infected cystic fibrosis (CF) patients. Membranes were probed with indicated 
antibodies (1µg/ml antibody), using pThr73-Rab10 and Total Rab10 to investigate LRRK2 activity resulting from P. aeruginosa strain infection. MLi2 treatment was 
verified by immunoblotting with pS935-LRRK2 antibody. GAPDH was used as an internal loading control. (Bottom) Quantification of immunoblots analysed through 
pT7-Rab10/ total Rab10 ratio shown for each strain. As significant cell death was observed at 4h upon infection of neutrophils with Strain B, pT73-Rab10 /Total 






FIGURE 3.3: Increased LRRK2-dependent Rab10 phosphorylation following infection of human peripheral blood neutrophils (Donor 2) with P. 
aeruginosa clinical isolates (uncharacterised Strains ‘A-D’)  
Methodology as described above in FIGURE 3.2 legend for top and bottom panels. Similar cell death at 4h using P. aeruginosa ‘Strain B’ was also observed in 




3.2 Investigating LRRK2 activity within sputum neutrophils from cystic fibrosis 
(CF) patients with chronic P. aeruginosa infections 
 
Given that increased LRRK2-dependent Rab10 phosphorylation at Thr73 was observed in 
peripheral blood neutrophils infected with P. aeruginosa strains, I next investigated whether 
LRRK2 activation can be observed in neutrophils isolated from the sputum of CF patients, who 
are frequently infected with P. aeruginosa, and thus harbour the pathogen in their sputum. To 
achieve this, I directly isolated neutrophils from sputum samples provided from multiple CF 
patients with recent infective exacerbations (with prior P. aeruginosa infection), and obtained 
un-infected control samples of a) sputum neutrophils isolated from the sputum of a patient with 
Primary Ciliary Dyskinesia (PCD), and b) peripheral blood neutrophils from a healthy blood 
donor. All isolated neutrophils were pre-treated with/without 200nM MLi2 and levels of pThr73-
Rab10 analysed within the lysates by immunoblotting. Thus, the aim of this experiment was 
to provide useful initial insight into the role of LRRK2 activity during chronic infection in CF 
patients, which could be carried forward for future work. 
3.2.1 Increased Rab10 phosphorylation observed within sputum neutrophils from CF 
patients 
Figure 3.4A reveals data from the initial experiment analysing LRRK2 activity in sputum 
neutrophils isolated from 5 infected CF patients (Donors 2-7), compared with 2 non-CF un-
infected sputum (Donor 8) and blood (Donor 1) neutrophil controls. Notably, all CF sputum 
neutrophil lysates demonstrated elevated pThr73-Rab10/Total Rab10 signal compared to 
control sputum/blood neutrophil lysates, of which pThr73-Rab10 signal was confirmed to be 
LRRK2 dependent through its elimination with MLi2 treatment. This suggests considerably 
high LRRK2 activity occurring within CF neutrophils. Quantification of Rab10 phosphorylation 
normalised to Total Rab10 revealed large variation in Rab10 phosphorylation between CF 
donors (Figure 3.4B, upper band), with Donor 5 exhibiting the highest increase in Rab10 
phosphorylation. Moreover, levels of total Rab10 also appeared to differ between CF donors, 
which could point to alterations in expression following infection. However, from the small 
number of CF infected sputum samples alongside un-infected controls, the current work could 
not demonstrate statistically significant differences in Rab10 phosphorylation between 
samples, or investigate for key expression differences in Rab10 between individual samples.  
Immunoblotting against p.p38 revealed variability in levels observed between CF sputum 
samples, suggesting differences in the amount of infection present in each sputum sample. 
This variability could be due to several factors including the chronicity of infection during which 
samples were taken, or the type or number of pathogens present in the samples. Interestingly, 
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whilst CF Donor 5 exhibited the highest level of Rab10 phosphorylation, levels of p.p38 
appeared the lowest compared to other CF samples. Reduced p.p38 signal could be due to 
chronic rather than acute infection, or due to a reduced level of infection itself. Thus, future 
work would require sputum culture analysis from each donor to confirm the type and number 
of pathogens present within the samples, and to then make correlations between p.p38/Total 
p38 and pThr73-Rab10/Total Rab10 ratios.  
Between the uninfected blood/sputum control donors, sputum neutrophils from Donor 8 
demonstrated a higher pThr73-Rab10/Total Rab10 signal ratio than that from peripheral blood 
neutrophils isolated from Donor 1, however this ratio was lower than all other sputum 
neutrophil samples from CF patients. p.p38 levels appeared low in both Donor samples, 
suggesting low levels of infection. It should also be noted that levels of total Rab10 were lower 
in Donor 8 compared to all other samples, in which the pThr73-Rab10 phosphorylation signal 
was also slightly reduced. Further work using more samples from PCD patients are needed to 
investigate whether these patients exhibit overall lower total Rab10 levels.  
As previously demonstrated for peripheral blood neutrophils in Figures 3.2 and 3.3, use of 
the LRRK2 antibody recognising the C-terminal domain of LRRK2 revealed that the 170kDa 
truncated form of LRRK2 appeared in higher abundance in sputum neutrophils compared to 
the full length 250kDa form. Quantification of LRRK2 phosphorylation at Ser935 normalised 
to Total LRRK2 for each donor revealed that Ser935 phosphorylation was reduced upon MLi2 
treatment in both full length (Figure 3.4B, middle band) and 170kDa N-terminally truncated 
LRRK2 species (Figure 3.4B, lower band), albeit to varying extents. Interestingly, Donor 5 
demonstrated the highest level of Rab10 phosphorylation compared to all other donors, 
however had one of the lowest levels of LRRK2 phosphorylation at Ser935, in both LRRK2 
species. Conversely, Donor 1 (blood neutrophil control) showed the highest LRRK2 
phosphorylation at Ser935 compared to all other donors in both species, despite having the 
lowest Rab10 phosphorylation. A similar finding had been previously noted in peripheral blood 
neutrophils from a PD patient possessing a G2019S mutation, who had relatively high levels 
of LRRK2 Ser935 phosphorylation, despite having low levels of Rab10 phosphorylation79. 
Together, my findings may illustrate that using LRRK2 Ser935 phosphorylation to investigate 








FIGURE 3.4A: Preliminary data of increased Rab10 phosphorylation indicative of LRRK2 activity within 
sputum neutrophils isolated from infected cystic fibrosis (CF) patients  
Immunoblot analysis of sputum neutrophils (pre-treated with/without 200nM MLi2 for 30 minutes) isolated from: 
6 different cystic fibrosis (CF) patients (Donor 2-7), a patient with primary ciliary dyskinesia (PCD, Donor 8), 
and peripheral blood neutrophils isolated from a healthy donor (Donor 1). Membranes were probed with 
antibodies (1µg/ml antibody); pT73-Rab 10 and Total Rab10 to investigate LRRK2 activity. GAPDH was used 































FIGURE 3.4B: Quantification of pRab10/Total Rab10 (Upper bands) and pSer.935/Total LRRK2 full 
length and 170kDa species (Middle, Lower bands) 
(Upper) Quantification of immunoblot results from Figure 3.4A reveal that pThr-Rab10/Total Rab10 ratio is 
highest in sputum neutrophils isolated from CF patients (Donors 2-7), with Donor 5 revealing the highest 
increase in ratio. (Middle, Lower bands) Contrastingly, peripheral blood neutrophils isolated from Donor 1 
(control) demonstrated the highest pS935-LRRK2/Total LRRK2 ratios compared to all other neutrophil donors, 
of both full-length and 170kDa species.  
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3.3 Investigating LRRK2 activity within mouse BMDMs infected with P. aeruginosa 
 
Previously published work has investigated LRRK2 activation in response to infection in 
mouse bone marrow derived macrophages (BMDMs) with several intracellular pathogens44,53, 
however LRRK2 activation following P. aeruginosa infection does not yet appear to have been 
explored. As discussed in 1.1.2, previous work within the Alessi lab revealed that activation of 
immune signalling pathways using MyD88-dependent pathway agonists resulted in LRRK2 
Ser935 phosphorylation, which was shown to be mediated by the IKK kinase family49 (Figures 
1.4 and 1.5). Other published work has revealed that LPS and flagellin produced by P. 
aeruginosa respectively stimulate TLR 2/4 and TLR 5 in mouse alveolar macrophages59.  
Thus, I hypothesised that P. aeruginosa infection in mouse BMDMs would similarly lead to 
LRRK2 Ser935 phosphorylation through activation of MyD88-dependent pathways, and if so, 
I investigated whether this was also due to IKK kinase control. Additionally, I investigated 
whether P. aeruginosa infection would lead to an increase in LRRK2-dependent Rab10 
phosphorylation in mouse BMDMs, which previous work has not yet explored. 
3.3.1 Increased LRRK2 Ser935 phosphorylation following PAO1 infection in WT 
BMDMs  
As hypothesised, infection of mouse BMDMs with P. aeruginosa PAO1 resulted in a 
progressive increase in LRRK2 phosphorylation at Ser935 (pSer935-LRRK2) over a 0.5 - 4 
hours infection time-course (Figure 3.5). PAO1 infection at 50 MOI resulted in a more rapid 
increase in pSer935-LRRK2 levels compared to 10 MOI, however phosphorylation levels were 
reduced by 4 hours of infection. Significantly, whilst basal pSer935-LRRK2 in uninfected WT 
BMDMs was abolished following 1 hour of 200nM MLi2 treatment, pSer935-LRRK2 was 
restored in MLi2 treated cells in the presence of 4 hours of PAO1 infection. The presence of 
Penicillin-Streptomycin (P/S) antibiotics within the culture medium of BMDMs with PAO1 
infection (4-hour duration) revealed no change in LRRK2 Ser935 phosphorylation at either 
MOI 10 or 50. MLi2 or P/S treatments at other timepoints (0.5-2h) in this initial experiment 
shown in Figure 3.5 were not assessed.  
Despite the progressive increase in pSer935-LRRK2 levels, PAO1 infection at either MOI 10 
or 50 appeared to have no effect on pThr-Rab10 levels in BMDMs, despite high expression 
levels of total Rab10 protein observed. In contrast, BMDMs treated with CNF3, a cytotoxic 
necrotising factor produced from pathogenic E. coli, produced a clear signal for Rab10 
phosphorylation. Experiments confirming CNF3 in inducing Rab10 phosphorylation in mouse 
BMDMs has been previously demonstrated by Dr Ying Fan in unpublished work conducted 
within the Alessi lab, hence was used as a control to assess Rab10 phosphorylation in my 
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experiment. The mechanism of how CNF3 induces Rab10 phosphorylation in BMDMs is not 
yet understood, however it is likely to activate a different upstream pathway of LRRK2 
compared to P. aeruginosa.  
Interestingly, immunoblotting against p.p38 in infected WT BMDMs revealed that p.p38 
activation was highest at early timepoints (0.5 and 1 h) and reduced over the remaining 2 and 
4 hour infection durations, which was seen at both MOI 10 and 50. This could be explained by 
a rapid activation response of the p38 MAPK signalling pathway upon infection in BMDMs, 
which reduces in intensity with increasing infection duration. This could explain the reduced 
p.p38 level despite high pThr-Rab10/Total Rab10 ratio observed in Donor 5, who may have 
had a longer duration of chronic infection compared to other CF donors (Figure 3.4). 
3.3.2 Increased LRRK2 Ser935 phosphorylation following PAO1 infection in Rab29 KO 
BMDMs 
Following recent work conducted within the Alessi lab which suggested that Rab29 may 
regulate basal phosphorylation of LRRK2 serine biomarker sites35, I investigated whether 
LRRK2 Ser935 phosphorylation can still be induced in Rab29 knockout (KO) mouse BMDMs 
cells by PAO1 infection. The use of Rab29 knockout BMDMs was confirmed through 
immunoblotting for Rab29 with the Rab29 total antibody, which was detected only in the WT 
BMDM control.  
Interestingly, progressively increasing levels of pSer935-LRRK2 were still observed within 
PAO1 infected Rab29 KO BMDMs, which was not eliminated with MLi2 treatment (Figure 
3.6). Furthermore, no observable Rab10 phosphorylation was observed in PAO1 infected 
Rab29 KO BMDMs, however was observed in Rab29 WT/KO control cells treated with 20 
hours CNF3. As observed in WT BMDMs, immunoblotting with p.p38 was highest at earlier 
timepoints (0.5 and 1 h). Collectively, these results demonstrate that Rab29 is not required for 






FIGURE 3.5: Increased LRRK2 Ser935 phosphorylation following P. aeruginosa PAO1 infection in wild-
type (WT) BMDMs  
(Top) Primary BMDMs were infected with PAO1 strain (MOI 10 or MOI 50) lasting for 0.5-4 hours. BMDMs were 
treated either with DMSO or 200nM MLi2 for 1 hour prior to infection, of which 0 and 4 hour infection was used 
in MLi2 treated cells. In addition, BMDMs cultured in media containing Penicillin/Streptomycin (P/S) were 
infected with PAO1 for 4 hours. Membranes were probed with the indicated antibodies (1μg/ml antibody), with 
GAPDH used as an internal loading control. WT BMDMs treated with +/- CNF3 for 20 hours were used as 
controls. (Bottom) Quantification of immunoblots analysed through pS935-LRRK2/Total LRRK2 for both MOI 









FIGURE 3.6: Increased LRRK2 Ser935 phosphorylation following P. aeruginosa PAO1 infection in 
Rab29 knockout (KO) BMDMs (7B) 
(Upper) Experiment design as described in Figure 3.5, but using Rab29 KO BMDMs, with Rab29 KO and 
WT BMDMs treated +/- CNF3 for 20 hours were used as controls. (Lower) Quantification of immunoblots 
analysed through pS935-LRRK2/Total LRRK2 for both MOI 10 and MOI 50 experiments.  
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3.3.3 LRRK2 Ser935 phosphorylation following PAO1 infection in BMDMs is mediated 
by ‘canonical’ and ‘non-canonical’ IKK kinases 
Following the results obtained in Figures 3.5 and 3.6, I set out to investigate whether both 
‘canonical’ and ‘non-canonical’ IKK kinases were responsible for the LRRK2 Ser935 
phosphorylation observed with PAO1 infection. Previous work from the Alessi lab 
demonstrated that to block LRRK2 Ser935 phosphorylation in mouse BMDMs treated with 
various MyD88-dependent agonists, it was necessary to pre-treat cells with a pharmacological 
inhibitor of TAK1 (Oxozeaenol), in conjunction with inhibitors of TBK1/ IKKε (MRT77307) 
(Figure 1.5)49. Thus, I followed the same experimental procedure by pre-treating mouse 
BMDMs for 1 hour with NG25 (alternative TAK1 inhibitor) and MRT77307, either in isolation 
or in combination, prior to infection with PAO1 for 0.5-4 hour time durations. Additionally, I 
assessed the impact of MLi2 treatment in BMDMs to investigate whether LRRK2 plays a role 
in controlling infection-induced Ser935 phosphorylation. 
As previously observed, a progressive increase in LRRK2 phosphorylation at Ser935 following 
increasing durations of PAO1 infection was demonstrated in DMSO controls (Figure 3.7). 
However, upon combined use of NG25+MRT77307 IKK kinase inhibitors at 1 and 2 hours, 
Ser935 phosphorylation was markedly reduced to below uninfected levels, which was a 
considerably stronger reduction compared with their individual use (Figure 3.7, lower right). 
This mirrors what has been previously demonstrated for combined use of TAK1/TBK1 and 
IKKε inhibitors (Figure 1.5)49. Immunoblotting for p.p38 revealed an increased signal upon 
PAO1 infection (uninfected compared to 0.5h infection), however the intensity of p.p38 signal 
decreased over the length of infection, as seen in Figures 3.5 and 3.6. Use of the TAK1 
inhibitor abolished p.p38 signal, which was demonstrated in previous work (Figure 1.5)49. 4 
hours of infection in the presence of TAK1 inhibitors was lethal to BMDMs, shown by the 
significant reduction of GAPDH signal in these lanes. 
Interestingly, a Ser935 phosphorylation reduction was observed with MLi2 treatment during 
0.5, 1 hour and 2- hour PAO1 infection in BMDMs, although to not the same extent of 
combined inhibitor treatment. However, by 4 hours of PAO1 infection, Ser 935 phosphorylation 
was restored to untreated levels, as observed in Figure 3.7.  Interestingly, in MLi2 treated 
cells, p.p38 signal gradually re-appeared at longer time durations (2-4 hours) of PAO1 
infection. Collectively, these findings could suggest that LRRK2 kinase maintains some control 
over basal Ser935 phosphorylation during early infection.. However, with increasing infection 
duration, LRRK2 control over Ser935 phosphorylation appears to weaken, either by being 
overpowered by TAK1/TBK1 and IKKε control, or through P. aeruginosa inhibition of LRRK2 
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phosphatases that control Ser935 dephosphorylation. These possibilities will be further 
explored in the discussion below (5.2.4) 
3.3.4 LRRK2 Ser935 phosphorylation following P. aeruginosa clinical isolate ‘Strain A’ 
infection in BMDMs is also mediated by canonical and ‘non’ canonical IKK kinases 
In order to investigate whether other strains of P. aeruginosa also resulted in LRRK2 Ser935 
phosphorylation, I infected WT BMDMs as above, but used the P. aeruginosa clinical isolate 
‘Strain A’ for 1 and 2 hour durations. Given that the data from Figure 3.7 revealed significant 
BMDM cell death following TAK1 inhibition in the presence of P. aeruginosa for over 4 hours, 
this time-point was not included for infection experiments using ‘Strain A’.  
Figure 3.8 demonstrates that P. aeruginosa ‘Strain A’ causes a marked increase in Ser935 
phosphorylation at both 1 and 2 hour infection durations compared to uninfected samples. 
However, in the presence of both NG25+MRT77307 IKK kinase inhibitors, Ser935 
phosphorylation was significantly reduced, showing a greater reduction at 2 hours of infection. 
MLi2 appears to show some reduction in Strain A induced Ser935 phosphorylation, however 
has a less reductive effect compared to its use in BMDMs with 2 hours of PAO1 infection.  
Comparing ‘Strain A’ with PAO1 infection, 2 hour infection with PAO1 produced a lower 
Ser935 phosphorylation signal compared to that with ‘Strain A’, which was lower than even 1 
hour infection with Strain A. This suggests that ‘Strain A’ may enhance LRRK2 Ser935 
phosphorylation to a greater degree than PAO1, potentially through activating other kinases 
that have not been inhibited. Indeed, whilst dual NG25+MRT77307 inhibitor use also resulted 
in a significant reduction of Ser935 phosphorylation (by ~75% at 2 hours of infection) in ‘Strain 
A’ treated BMDMs, residual Ser935 phosphorylation remained compared to in uninfected 
BMDMs. Overall, understanding how different P. aeruginosa strains may be controlled by a 
different balance of kinases would be interesting for future work to explore.
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FIGURE 3.7: IkappaB kinases (TAK1 and TBK1/IKKε) contribute to LRRK2 Ser935 phosphorylation following P. aeruginosa PAO1 infection in 
primary mouse bone marrow derived macrophages (BMDMs) 
Primary mouse BMDMs were treated with either DMSO, 2µM NG25 (TAK1 inhibitor), 2µM MRT67307 (TBK1/IKKε inhibitor), 200nM MLi2 alone or in the indicated 
combinations for 1 hour before infection with PAO1 strain (MOI 10) lasting for 0.5,1,2,4 hour durations. Cell lysates were subjected to immunoblot analysis with the indicated 
antibodies. (Upper Right) Quantification of immunoblots analysed for pS935-LRRK2/Total LRRK2 ratios in DMSO compared to MLi2 treated BMDMs at each infection time-




























FIGURE 3.8: IkappaB kinases (TAK1 and TBK1/IKKε) contribute to LRRK2 Ser935 phosphorylation 
following P. aeruginosa clinical isolate ‘Strain A’ infection in primary mouse BMDMs 
(Upper) As in Fig. 3.7; mouse BMDMs were treated with either DMSO, 2µM NG25 (TAK1 inhibitor), 2µM 
MRT67307 (TBK1/IKKε inhibitor), 200nM MLi2 alone or in the indicated combinations for 1 hour before infection 
with P. aeruginosa uncharacterised clinical isolate ‘Strain A’ (MOI 10) lasting for 1 or 2 hour durations. WT BMDMs 
treated with either DMSO, 2µM NG25+MRT67307 (combination TAK1 and TBK1/ IKKε inhibitor) and MLi2 for 1 
hour were infected in parallel with PAO1 strain for 2 hours. Cell lysates were subjected to immunoblot analysis with 
the indicated antibodies.  
(Lower) Quantification of immunoblots analysed for pS935-LRRK2/Total LRRK2 ratios using all inhibitors at 1 hour 




4. CHAPTER 4 - PROJECT B RESULTS 
For Project B, the primary aim was to investigate whether I could detect stabilised PINK1 
within human peripheral blood neutrophils. If achievable, these cells could henceforth be 
recommended as a valuable human cell source to directly investigate the PINK1/Parkin 
pathway, and compare levels of activity between PD patients and healthy individuals.  
Before conducting the relevant experiments, I investigated for existing published evidence of 
mRNA expression of PINK1 within human peripheral blood neutrophils. Microarray and RNA-
sequencing data available on the Expression Atlas database revealed that PINK1 mRNA 
expression is present within several human neutrophil sources, albeit to a much lower level 
than that of LRRK2, Rab10 and Rab8A (Figure 4.1). Parkin expression was found to be very 
minimal, and only minutely present in mature neutrophils. Therefore, given evidence of some 
PINK1 mRNA expression in human neutrophils, I began to conduct experiments to observe if 
activated PINK1 can be detected in human peripheral blood neutrophils following CCCP 
treatment. PINK1 activation would be detected either through the presence of stabilised PINK1 
protein, or through detection pUb as a readout of PINK1 activity; using antibodies targeted to 












FIGURE 4.1: Graphical expression of gene expression for Rab8A, Rab10, Parkin, PINK1, LRRK2, 
GAPDH in several human neutrophil sources 
Gene expression, according to transcripts per million, was collected from the online database Expression 
Atlas (https://www.ebi.ac.uk/gxa/home). GADPH was used as a gene expression standard. PINK1 
expression is present in all human neutrophil sources, albeit considerably lower in segmented bone marrow 
neutrophils compared to LRRK2 and GAPDH, as well as Rab10 and Rab8A. Parkin expression was not 
present in these cell types. 







Transcripts per million (TPM): GAPDH LRRK2 PINK1 Parkin Rab10 Rab8A
Segmented neutrophil of bone
marrow
669 494 44 104 47
Neutrophillic metamyelocyte 1295 28 15 116 28
Mature neutrophil 592 256 23 0.7 36 33













FIGURE 4.2: Interrogating for PINK1 activity following CCCP stimulation in peripheral blood neutrophil 
whole cell lysates.  
Immunoblot analysis of peripheral blood neutrophils stimulated with 10μM CCCP over 3-20h time course, using 
HEK293 PINK1 knockout and PINK1 knockout cells re-expressing PINK1-3X FLAG (3h CCCP) as controls. Of 
note, 9h time-course was not used for Donor 2. (Upper) Probing the membrane with the anti-PINK1 (Novus 
Biologicals) antibody revealed presence of 3 species increasing at molecular weights of 75, ~60 (red box) and 
20 with increasing CCCP durations. The ~60kDa species was originally considered as potentially activated 
PINK1, but deemed unlikely due to the similar weighted band in PINK1 KO control. (Middle) Probing with pUb 
antibody did not show any notable smear for pUb at any time point, compared to in the stimulated PINK1 control. 
(Lower) Probing with anti-Tubulin antibody demonstrated reduced protein lysate for both neutrophil donors at 






FIGURE 4.3: Interrogating for Parkin expression following CCCP stimulation in peripheral blood 
neutrophils 
As above in Figure 4.2, the membrane was probed with the anti-Parkin (SantaCruz) antibody which did not 
reveal evidence of Parkin expression at the expected molecular weight (52kDa), however was strikingly 
observed as a larger smear in the PINK1 positive and negative HEK293 controls. 3 species increasing at 
molecular weights of 75, ~60 and 20 with increasing CCCP durations was also observed, which is likely to 
be due to non-specific binding as observed in Figure 4.2 with the PINK1 (Novus) antibody.  
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4.1 Immunoblot analysis of peripheral blood neutrophils treated with CCCP 
 
Initial immunoblot analysis of peripheral blood neutrophil lysates treated with 10µM CCCP and 
probed with the PINK1 polyclonal (Novus) antibody revealed 3 species migrating at 75kDa, 
~60kDa and 20kDa, which appeared in a time-dependent manner after 9 or 20 hours CCCP 
treatment in both donors (Figure 4.2). Whilst the band around 60kDa appeared near the 
molecular weight expected for stabilised PINK1 (~63kDa, red box) a similar weight band was 
also seen in both HEK293 PINK1 knockout and PINK1 knockout cells re-expressing PINK1-
3X FLAG wild-type (WT) (PINK1 positive control) lysates, suggesting it may be a non-specific 
band caused by cross-reactivity of the anti-PINK1 antibody with any degradation proteins 
present within neutrophils. Indeed, a larger isolated band appearing above the 60kDa species 
is only present within the HEK293 PINK1 positive control lysate, which is suggestive of over-
expressed PINK1. Probing the membrane with anti-pUb antibody also did not show any 
characteristic signal smear in either donor at any time point, in contrast to the strong pUb 
signal seen in the HEK293 PINK1 positive control (Figure 4.2).  
Upon probing the membranes for Parkin (Figure 4.3), no evidence of Parkin at the predicted 
molecular weight (52kDa) could be observed at any timepoint, which corroborates with 
previous Expression Database findings of minimal Parkin mRNA expression in human 
neutrophil sources (Figure 4.1). This is in contrast to the high intensity Parkin bands observed 
in both HEK293 PINK1 positive and negative controls, which both contain high Parkin 
expression. Interestingly, 3 species migrating above 75kDa, ~60kDa and 20kDa which 
increased in a time-dependent manner was observed in stimulated peripheral neutrophils 
probed for Parkin, similar to those seen when probing for PINK1 in Figure 4.2.  
Collectively, the results suggest a lack of identifiable PINK1 or substrate activation in 
peripheral blood neutrophils following CCCP stimulation, and appear to demonstrate non-
specificity in the bands recognised by antibody probing. Thus, in order to assess PINK1 
activation in neutrophils following CCCP stimulation in account for potential low-expression, I 
subsequently conducted PINK1-immunoprecipitation experiments. Given that 20h stimulation 
with 10μM CCCP did not appear to be tolerated by neutrophils, evidenced by the reduced anti-
Tubulin levels despite loading consistent levels of protein for each sample in Figure 4.2, the 



























FIGURE 4.4: Immuno-precipitation of PINK1 from HEK293 PINK1 knockout cells and PINK1 knockout 
cells stably re-expressing PINK1-3X FLAG cells (24h doxycycline, 3h CCCP) 
(A) 1mg of whole cell lysates were stimulated with CCCP and subjected to immunoprecipitation (IP) with PINK1 
antibody (S085D) covalently coupled to protein G Sepharose beads. 75% of the IP was immunoblotted with anti-
PINK1 (Novus) antibody, alongside 20µg of both whole cell lysate (input) and IP supernatant. (B) Western blot of 
PINK1 IP demonstrating comparable efficiency of PINK1 (S085D) coupled to protein G Sepharose beads (α-P) 
against anti-FLAG agarose beads (α-F), immunoblotted with anti-PINK1 (Novus), with quantification of PINK1 






4.2 Optimisation of PINK1 immuno-precipitation and endogenous PINK1 
expression control experiments  
 
Prior to investigating PINK1 activation in peripheral blood neutrophils through immuno-
precipitation (IP) experiments, I first optimised PINK1 IP based detection in cells with high 
PINK1 expression. Figure 4.4A shows initial testing of PINK1 (in-house S085D, 3rd bleed) 
antibody coupled with Protein G Sepharose beads in HEK293 FLP-In T-rex PINK1 knockout 
stably re-expressing PINK1-3X FLAG cell lysates (3h CCCP), confirming successful IP of 
PINK1 protein on Western blot. Figure 4.4B demonstrates that the PINK1 S085D IP beads 
were comparable in efficiency to commercially available anti-FLAG agarose beads, validating 
their subsequent use on stimulated whole cell neutrophil lysates (Figure 4.6). 
In order to compare the detection of endogenous, rather than oxer-expressed, PINK1 in cell 
lysates to that in peripheral blot neutrophils, I used WT/PINK1 KO HeLa cells as controls for 
final experiments. Western blot analysis of whole cell HeLa WT/KO lysates treated with 10μM 
CCCP or combination 10μM Antimycin/1μM Oligomycin for 22 hours revealed that 
endogenous PINK1 can be detected in WT treated samples when probed with the anti-PINK1 
(Novus) antibody (Figure 4.5). Use of CCCP as a mediator of mitochondrial depolarisation 
produced a stronger PINK1 band than the Antimycin/Oligomycin treatment combination, 
henceforth WT/PINK1 KO HeLa cells treated with CCCP were used for final neutrophil IP 
experiments as positive endogenous PINK1 controls (Figure 4.6). Several other PINK1 
antibodies were also trialled (data not shown), however the anti-PINK1 Novus antibody 
produced the strongest signal that was both sensitive and specific for PINK1 detection in whole 







FIGURE 4.5: Western 
blot demonstrating 
PINK1 activation in 
endogenous wild-type 
(WT) and PINK1 knock-
out (KO) HeLa whole cell 
lysates 
 WT and PINK1 KO HeLa 
cells were treated with +/- 
10μM CCCP or +/- 
combination 10μM 
Antimycin/1uM Oligomycin  
(A/O) for 22 hours. 40μg 
whole cell lysates were 
immunoblotted and 
probed using the anti-
PINK1 (Novus) antibody. 
A stronger band at 55kDa 
indicative of stabilised 
PINK1 appears using 22h 
CCCP compared to A/O. 
  




FIGURE 4.6: Absence of PINK1 in peripheral blood 
neutrophils upon CCCP stimulation 
(Upper) No observable species corresponding to the molecular 
weight of stabilised PINK1 (~63kDa) are seen from Immunoblot 
analysis of PINK1 immuno-precipitates from peripheral blood 
neutrophils stimulated with a 10μM CCCP time-course in either 
Donor 3 or 4, probed for PINK1 using the anti-PINK1 (Novus) 
antibody. A clear band for PINK1 is observed within the PINK1 
positive control from WT HeLa immuno-precipitate (22h CCCP), 
confirming the IP efficiency. (Lower) Ponceau stain of membrane 
(Donor 3) is shown as a loading control. 
  




4.3 Final investigation of PINK1 activation within stimulated peripheral blood 
neutrophils through IP experiments  
 
Having optimised IP PINK1 detection, I undertook a time-course of neutrophil stimulation with 
10μM CCCP for 3-12 hours in neutrophils isolated from two donors (Donor 3 and 4), and then 
performed IP experiments of the lysates. Immunoblot analysis of 750μg neutrophil PINK1 
immuno-precipitates probed with the anti-PINK1 antibody (Novus) did not show any bands 
suggestive of endogenous PINK1 presence at any timepoint, in either donor (Figure 4.6). In 
comparison, a strong band for endogenous PINK1 could be visualised from an equivalent 
amount of 750μg Hela WT PINK1 immuno-precipitate, stimulated with 22 hours of CCCP.  
Collectively, the results support previous data from Figure 4.2, that endogenous PINK1 cannot 
be detected in peripheral blood neutrophils following 10μM CCCP stimulation of up to 12 
hours. Suggestion future experiments to continue on from the current experiments will be 



















5. CHAPTER 5 –DISCUSSION  
5.1 Results overview 
 
The following paragraphs focus on the key findings and mechanistic possibilities from my 
results in Project A and B in the context of current literature, upon which I discuss further 
improvements of each project for future work.  
Overall, my findings within Project A add to the growing body of research connecting LRRK2 
with infection. In accordance with the main aims of Project A, I explored the impact of ex-vivo 
P. aeruginosa infection on LRRK2 activity within human peripheral blood neutrophils and 
mouse BMDMs. Interestingly, I found that P. aeruginosa infection in human peripheral blood 
neutrophils led to an increase in LRRK2-dependent Rab10 phosphorylation, but not in mouse 
BMDMs, despite both cell types expressing high levels of the LRRK2 protein (Figure 5.2). I 
also observed variable differences in cytotoxicity and the level of Rab10 phosphorylation 
induced in neutrophils depending on the P. aeruginosa strain utilised, including strain PAO1 
and clinical isolate strains (‘A-D’) from chronically infected CF patients. Moreover, I 
demonstrated that P. aeruginosa infection in mouse BMDMs resulted in a steady increase in 
LRRK2 Ser935 phosphorylation, and confirmed that this was mediated through the IKK 
kinases. In my preliminary experiments using neutrophils isolated from sputum samples of 
infected CF patients with previous P. aeruginosa infection, I also found considerably high 
levels of LRRK2-dependent Rab10 phosphorylation, suggesting high levels of LRRK2 activity 
occurring within these cells.  
My findings within Project B demonstrated that PINK1 stabilisation could not be detected in 
peripheral blood neutrophils following treatment with CCCP for up to 12 hours. Given that 
previous work has revealed that neutrophils have a low expression of PINK1 mRNA, these 
cells may not be a beneficial cell type to observe PINK1/Parkin activity, despite being a readily 








5.2 Project A Discussion 
5.2.1 Influence of P. aeruginosa strains on LRRK2-dependent Rab10 phosphorylation 
within infected peripheral blood neutrophils 
My results in Figures 3.1-3.3 revealed that infection of human peripheral blood neutrophils 
with different strains of P. aeruginosa led to increased LRRK2-dependent Rab10 
phosphorylation at Thr73 (pThr73-Rab10), suggesting that the P. aeruginosa strains I used 
may have similar mechanisms of enhancing LRRK2 activity. However, there were notable 
differences in the rate of Rab10 phosphorylation induced between the strains, as well as in 
their cytotoxicity. For example, significant neutrophil death in both Donor 1 and 2 was uniquely 
seen following 4-hour infection with Strain B (Figures 3.2-3.3). Furthermore, a band-shift in 
several Rab proteins including Rab10, Rab 7 and Rab8A was only observed with the PAO1 
strain (Figure 3.1) 
Collectively, these observed differences could be due to distinct host-dependent adaptions of 
P. aeruginosa strains according to the unique lung environments of each CF individual from 
which they were isolated, including differential antibiotic use and poly-microbial exposure. As 
discussed in 1.3.1, P. aeruginosa strains have shown to alter their phenotypic and genotypic 
properties over the time-course of colonization within CF individuals, whereby isolates from 
chronically infected CF patients more readily form biofilms and overexpress the 
exopolysaccharide alginate than strains isolated from the same patients at earlier timepoints97. 
Interestingly, later strains appear less inflammatory and cytotoxic; they lack key inflammatory 
bacterial features, such as flagella and pili, and have a downregulated type 3 secretion system 
(T3SS)98. Hence, it is possible that Strain B was isolated from a less-chronically infected CF 
patient compared to others, thus had higher cytotoxic properties when used within neutrophils. 
Exploring whether adaptions in the inflammatory and cytotoxic properties of different P. 
aeruginosa strains can influence LRRK2-dependent immune signalling pathways necessitates 
further experimentation. For example, mass spectrometry analysis could investigate for 
LRRK2 interactors upregulated in neutrophils with each strain infection, as well as 
investigation for the types, amounts and rates of inflammatory markers or cytokines produced. 
Moreover, to assess whether changes within the same P. aeruginosa strain over time could 
influence LRRK2 activity, a future experiment design could isolate P. aeruginosa strains at 
different time-points from the same infected CF individual (such as through sputum collections 
from regular CF clinic appointments), and then investigate differences in the level or rate of 
LRRK2-dependent Rab10 phosphorylation induced upon infection of immune cells with these 
time-coursed strains. These experiments would provide useful observations over how 
evolutionary changes in P. aeruginosa could alter key cellular signalling pathways. 
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In order to assess for specific time-points of the band-shifts or cell toxicity induced by different 
strains, use of narrower infection duration margins (e.g. between 2-4 hours, when key changes 
appear to occur), would also be useful for future experiments. In addition, differences in the 
rate and amount of Rab10 phosphorylation observed per strain (Figures 3.2-3.3) may have 
been due to innate differences between the neutrophils themselves, such as in LRRK2/Rab10 
mRNA and protein expression. Therefore, greater numbers of neutrophil donors and biological 
replicates are also required in future work. 
5.2.2 Findings and future investigations of LRRK2 activity in CF sputum neutrophils 
during natural course of P. aeruginosa infection 
My results within Figure 3.4 revealed a novel finding that LRRK2-dependent Rab10 
phosphorylation was considerably elevated in sputum neutrophils isolated from CF patients 
with recent acute infective exacerbations (Donors 2-7), compared to levels within uninfected 
peripheral blood and sputum neutrophil control samples (Donors 1 and 8). Given that all CF 
patients had suffered from previous P. aeruginosa infections, it is likely that P. aeruginosa was 
present in the collected sputum samples. Based on the results of Figures 3.1-3, P. aeruginosa 
presence within CF sputum neutrophils can thus be hypothesised to have influenced the levels 
of Rab10 phosphorylation observed. Alternatively, the results could point to a unique role of 
LRRK2/Rab10 phosphorylation in CF sputum neutrophils themselves, where their expression 
and function may be different.  
Further exploration from these findings requires improvements of some of the current 
limitations within this experiment. Firstly, there may be generalised differences between 
sputum and peripheral blood neutrophils, including in LRRK2/Rab10 mRNA expression, 
hence the current comparison between the healthy peripheral blood neutrophil control (Donor 
1) with sputum neutrophil samples from CF patients is not optimal. Therefore, future work 
should isolate both sputum and peripheral blood neutrophils from each CF patient, and 
subsequently compare any differences in LRRK2/Rab10 mRNA expression, as well as 
resultant Rab10 phosphorylation. In addition, an equal number of peripheral blood neutrophils 
should be isolated from healthy blood donors, to compare Rab10 expression and 
phosphorylation levels between healthy and CF donors.  
Secondly, whilst sputum from a patient with PCD (Donor 8) was used as an uninfected 
‘sputum’ neutrophil control, it is possible that their sputum sample may also have contained 
some bacterial pathogens remaining from previous/latent infection, despite not having an 
‘acute’ exacerbation. Thus, to create more accurate sputum neutrophil comparisons in future 
work, an equal amount of sputum samples from non-CF patients and CF patients should be 
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collected, with sputum cultures obtained from all samples to confirm the presence and type of 
pathogens present. This would enable future experiments to assess LRRK2-dependent 
Rab10 phosphorylation only in the presence of select organisms, including P. aeruginosa. 
Bearing these improvements in mind, my findings within Figure 3.4 pave the way for a future 
clinical study to investigate LRRK2 activation during the natural time course of P. aeruginosa 
infection within CF patients. A schematic of the proposed study plan is outlined within Figure 
5.1. As a summary, sputum and blood samples would be collected from CF patients with 
chronic P. aeruginosa infection at a series of timepoints; a) at the start of an infective 
exacerbation prior to or within 48 hours of commencing antibiotic treatment, b) midway through 
antibiotic treatment, c) after the completion of antibiotic treatment and/or clinical improvement 
of patient symptoms. Samples would be respectively recorded as ‘acute’, ‘mid-acute’ or ‘post-
acute’ as a generalised description of their infection status. In parallel, blood samples would 
be taken from age and gender matched healthy donors (e.g. relatives of CF patients), and 
sputum and culture samples from non-CF uninfected individuals. Routine microbiological 
culture and sensitivity testing would be performed for all sputum samples, in which only 
sputum samples without P. aeruginosa presence would be used as control samples. 
Investigation into other organisms frequently cultured in the sputum of CF patients, and 
comparison of their effect on LRRK2 activity, could also form a subsection of the study.  
Following blood/sputum sample collection, all neutrophils would be directly isolated at each 
timepoint using the existing established protocols (described in Methods 2.3.1 and 2.3.2), 
treated with 200nM of MLi2/DMSO for 30 minutes, and lysates analysed together through 
immunoblotting to observe any change in LRRK2 activity over the infection time-course per 
donor. In addition, LRRK2 and Rab10 mRNA expression in both sputum and blood neutrophils 
from CF and non-CF patients at each collection would be assessed, in order to investigate for 
changes in transcription during the infection time-course. 
Based on my results obtained in Figures 3.1-3.4, it could be hypothesised that CF sputum 
neutrophil samples collected at the start of P. aeruginosa infection would contain the highest 
levels of LRRK2-dependent Rab10 phosphorylation; when LRRK2 activation in response to 
infection is greatest, and gradually decrease as infection reduces following antibiotic treatment 
(Figure 5.1). Alternatively, given that CF patients are frequently infected with several 
pathogens, LRRK2 levels may remain considerably higher compared to non-CF individuals 
suffering from intermittent and resolvable infections, and may even remain elevated for longer 
than the acute infection time-course itself. Hence, evaluation of these future results will provide 




5.2.3 Possible mechanisms behind LRRK2-dependent Rab10 phosphorylation in 
neutrophils during P. aeruginosa infection  
There are several possible mechanisms behind how P. aeruginosa infection in human 
neutrophils promotes LRRK2-dependent Rab10 phosphorylation. Firstly, P. aeruginosa 
infection in neutrophils may directly activate LRRK2 through production of a specific LRRK2 
activator, which could promote LRRK2 dimerization and localisation to the cell membrane. 
Alternatively, P. aeruginosa may act indirectly through activating an existing upstream 
activator of the LRRK2 signalling pathway, or promote the loss of/suppress the action of an 
upstream inhibitor of LRRK2. Either mechanism of LRRK2 activation would be expected to 
result in an increase of LRRK2-dependent Rab10 phosphorylation. Alternatively, P. 
aeruginosa infection may inhibit currently elusive Rab phosphatases specifically acting on 
FIGURE 5.1: Schematic of proposed large-scale clinical study plan to investigate LRRK2 activity 
following in-vivo P. aeruginosa infection in CF patients.  
Sputum and peripheral blood neutrophils would be collected from infected CF patients at 3 separate time-
points over the typical infection time-course (days-weeks) and recorded as ‘acute’, ‘mid-acute’ and ‘post-
acute’. Sputum/blood neutrophil lysates obtained from each donor would be assessed for changes in 
LRRK2 activity through immunoblotting for levels of LRRK2-dependent Rab10 phosphorylation at Thr73 
over the time-course of infection. In addition, control blood and sputum samples would be obtained from 
non-infected control individuals. 
Based on current results, it could be hypothesised that LRRK2 activity would be highest at the start of 
infection prior to treatment, and then reduce as the infection subsides following antibiotic treatment. 






LRRK2-phosphorylated Rab proteins. Several members of the Alessi lab are currently 
exploring potential Rab phosphatase candidates, thus once confirmed, would be useful to 
include in future experiments to investigate whether there are changes to their upregulation 
during P. aeruginosa infection. 
Alternatively, P. aeruginosa infection within neutrophils could result in alterations to Rab 
proteins themselves, which could potentially have negative-feedback effects on LRRK2 
activation. Indeed, the band-shifts of Rab proteins after 4 hours of PAO1 infection in peripheral 
blood neutrophils revealed in Figure 3.1 may be suggestive of post-translational modifications 
(PTMs) induced by P. aeruginosa. PTMs include the addition of various groups (phosphate, 
acetyl, methyl) onto specific amino acids, or proteolytic cleavage of protein chains99, which 
can collectively alter the activity, localization or interactions of modified proteins. In the context 
of Rab proteins, previous research in macrophages revealed that P. aeruginosa utilises its 
T3SS exotoxin ExoS to modify and downregulate Rab5 activity through ADP-ribosylation, 
enabling it to avoid destruction100. Specifically, Rab5 has been reported to play a critical role 
during the early stages of P. aeruginosa invasion in macrophages101, which controls epithelial 
junctions and phagocytosis, and is targeted for subversion. Future work could investigate 
whether P. aeruginosa causes PTMs in other Rab proteins known to be phosphorylated by 
LRRK2, and investigate potential residues on which these modifications may occur. 
Additionally, infection experiments utilising inactive P. aeruginosa strains or those with 
impaired/absent T3SS secretion systems could reveal the importance of these factors in the 
observed LRRK2 activation/ Rab phosphorylation.   
Crucially, it would be important to investigate whether possible PTMs induced by P. 
aeruginosa affect the ability of LRRK2 to phosphorylate Rab proteins. Interestingly, whilst an 
overall increase in Rab10 phosphorylation during P. aeruginosa infection was observed with 
most strains (Fig. 3.1-3.3), there was a slight dip in the levels of phosphorylated Rab10 by 4 
hours of PAO1 infection in neutrophils (Fig. 3.1), during which the band-shift of Rab proteins 
was also observed. This could potentially indicate a reduction in the ability of LRRK2 to 
phosphorylate PAO1-modified Rab10. Indeed, a type of PTM named ‘eliminylation’ leads to 
the irreversible removal of phosphate groups from proteins, which has been shown to be 
mediated by the ‘OspF’ family of type III effectors, including Pseudomonas HopAI1 
effectors102. Thus, certain P. aeruginosa effectors could harbour phosphatase activity which 
permanently reverses LRRK2-phosphorylation of Rab proteins, leading to irreversibly inactive 
Rab proteins and thus potential LRRK2 inactivation. Therefore, future experiments could also 
consider longer infection time-points to observe whether LRRK2-dependent Rab10 
phosphorylation alters with time, and if so, consider mass spectrometry analysis of the Rab 
proteins for any observable differences in phosphorylation of specific residues.  
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5.2.4 Future investigations and potential mechanisms of IKK mediated LRRK2 Ser935 
phosphorylation in mouse BMDMs during P. aeruginosa infection  
Regarding the P. aeruginosa infection experiments I conducted within mouse BMDMs, 
Figures 3.5-3.6 built on previous work from the Alessi lab49 by demonstrating that LRRK2 
Ser935 phosphorylation could be induced through infection of mouse BMDMs with P.  
aeruginosa (Figure 3.5). Ser935 phosphorylation was also induced in Rab29 KO BMDMs 
(Fig.3.6), providing evidence towards a Rab29-independent LRRK2 phosphorylation pathway 
induced by TLR agonists. An earlier study revealed that LRRK2 phosphorylation at its serine 
residues was followed by LRRK2 dimerization and membrane translocation in multiple mouse 
monocyte cell lines treated with the TLR4 agonist lipopolysaccharide (LPS)103. Specifically, 
whilst peak LRRK2 Ser935 phosphorylation was achieved by 4 hours of LPS treatment, 
significant dimerization and membrane translocation were only observed by 16 hours103. 
Hence, future work could also use longer time courses of P. aeruginosa infection in BMDMs 
to establish the time-point of peak LRRK2 Ser935 phosphorylation, alongside cellular 
fractionation and dimerization experiments to observe for changes in LRRK2 dimerization and 
membrane recruitment.  
Furthermore, Figures 3.7 and 3.8 revealed that LRRK2 Ser935 phosphorylation was 
controlled by the IKK kinases, whereby Ser935 phosphorylation was considerably reduced 
through dual inhibition of TAK1 with NG25 and TBK1/ IKKε with MRT67307 during both PAO1 
and clinical isolate ‘Strain A’ infection in BMDMs (Fig. 3.7 and 3.8). Interestingly, MLi2 
appeared to cause an initial reduction in LRRK2 Ser935 phosphorylation at early PAO1 
infection durations, however by 4 hours of infection had minimal effect, which is consistent 
with previous results (Figures 3.5 and 3.6). Understanding the specific relationship between 
LRRK2 and the IKK kinases during infection in other cell types would be useful for future work 
to explore. 
Collectively, my results may suggest that basal phosphorylation of LRRK2 at Ser935 in 
BMDMs is controlled by both LRRK2 kinase and IKK kinase activity, of which the latter is 
LRRK2 independent. Thus, basal phosphorylation can be eliminated by use of LRRK2 kinase 
inhibitors, such as MLi2, as well as IKK kinase inhibitors. However, upon activation of Toll-like 
receptors by P. aeruginosa ligands, Ser 935 phosphorylation may be gradually shifted towards 
IKK kinase control, which could explain the reduced ability of MLi2 to induce Ser935 
dephosphorylation with increasing infection durations, compared to dual IKK kinase inhibition.  
Another possible hypothesis is that P. aeruginosa inhibits the protein phosphatase which 
interacts with LRRK2 and promotes Ser935 dephosphorylation in mouse BMDMs, of which 
some studies have suggested protein phosphatase 1 (PP1) as a key phosphatase31. 
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Therefore, potential mechanisms of P. aeruginosa could involve novel protein-protein 
interactions between the regulatory subunits of PP1 with a specific P. aeruginosa effector, 
which could reduce the accessibility and interaction of PP1 with LRRK2. To investigate this 
possibility, mass spectrometry analysis for specific protein-protein interactors following P. 
aeruginosa infection in BMDMs should be assessed. However, it is possible that P. aeruginosa 
could inhibit interaction of PP1 with LRRK2 through a currently unknown mechanism. In 
addition, the IKK kinase pathway may not be regulated by P. aeruginosa, thus maintaining 
LRRK2 Ser935 phosphorylation unless the kinases themselves are inhibited.  
5.2.5 Differential LRRK2 activation between immune and host cell types  
It is intriguing that increased Ser935 phosphorylation of LRRK2 following P. aeruginosa 
infection was only observed in BMDMs, however not in neutrophils, where there was instead 
increased Rab10 phosphorylation (Figure 5.2). This raises an interesting possibility that 
LRRK2 has distinct forms or activation pathways within different immune cell types. For 
example, there may be cell-type specific LRRK2 differential splicing, whereby different cell 
types could express different LRRK2 isoforms according to their specific cellular functions. 
Alternatively, there may be different downstream pathways following from LRRK2 
phosphorylation or activation with immune cells, which could result in differential immune cell 
host responses to infection.  
Different signalling pathways upstream of LRRK2 may also operate between neutrophils and 
macrophages. Interestingly, previous work has revealed that human neutrophils exclusively 
use the “MyD88-dependent” pathway following activation of TLR4 by LPS, compared to 
monocytes which can utilise both MyD88 streams104. Given that LRRK2 Ser935 
phosphorylation was abolished in infected peripheral blood neutrophils pre-treated with MLi2 
(Figures 3.1-3.3), this could suggest that the MyD88-dependent pathway is regulated by 
LRRK2 activity. In contrast, the MyD88-independent pathway may be LRRK2-independent or 
additionally controlled by other kinases, which could explain why Ser935 phosphorylation was 
still preserved in BMDMs pre-treated with MLi2 (Figures 3.5-3.8), in which both MyD88-
dependent and independent pathways are functional in these cells.  
Another important factor to consider is that BMDMs and peripheral blood neutrophils were 
obtained from mice and humans respectively, thus differences in LRRK2 activation may be 
due to dissimilar mechanisms of P. aeruginosa infection in each species. Indeed, previous 
research involving Salmonella Typhi (S. Typhi) revealed significant host-specificity which was 
restricted to humans, whereby S. Typhi was unable to survive within mouse macrophages 
compared to human macrophages105. Although P. aeruginosa has shown to be capable of 
infecting a broad spectrum of species106, it would be useful for future experiments to similarly 
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investigate the survival and impact on LRRK2 activity of P. aeruginosa infection in human 
monocyte-derived macrophages, compared to in mouse BMDMs. This would provide further 
clarity of any species-specific differences of P. aeruginosa activation of LRRK2 activity, which 















FIGURE 5.2: Summary schematic of LRRK2 response to P. aeruginosa infection in experiments 
utilizing human peripheral blood neutrophils (left) and mouse BMDMs (right).  
P. aeruginosa infection in human neutrophils led to increased LRRK2-dependent Rab10 
phosphorylation at Thr73, of which the mechanism is currently unknown. Conversely, P. aeruginosa 
infection within mouse BMDMs led to increased LRRK2 phosphorylation at Ser935, which was 
mediated through activation of IKK canonical and non-canonical kinases downstream of the MyD88 
dependent and independent pathways.  
Understanding the downstream pathways following from Rab10 phosphorylation and LRRK2 Ser935 
phosphorylation within each immune cell, investigating for any cell or host specific differences in LRRK2 
response, and clarifying the overall beneficial or inhibitory response of LRRK2 to P. aeruginosa 





5.2.6 The role of LRRK2 in immune cells during P. aeruginosa infection 
The fundamental question remaining from all experiments conducted within Project A is 
whether LRRK2 plays a beneficial or deleterious role in the host immune response against P. 
aeruginosa. As discussed within 1.1.2, several studies utilising different pathogens have 
revealed complex and contrasting roles for LRRK2 in the immune response51,53, which are 
indeed likely to be immune cell and host cell dependent.  
On the one hand, given that neutrophils are vital for host defence against P. aeruginosa in 
healthy and immuno-competent individuals, the increase in Rab10 phosphorylation seen 
following P. aeruginosa infection in human peripheral blood and sputum neutrophils (Figures 
3.1-3.4) could be a beneficial host mechanism induced by LRRK2; such as through activating 
downstream signalling pathways involved in pathogen localisation to lysosomes and 
degradation. Interestingly, previous research has revealed that Rab10 is a positive regulator 
of TLR4 complex signalling, which is involved in activating an inflammatory response against 
LPS present on the outer membrane of Gram-negative bacteria107. Specifically, Rab10 co-
localises with TLR4 and promotes its transport from the Golgi to the plasma membrane upon 
exposure to LPS, replenishing TLR4 membrane receptors and thus enhancing host cell 
defence. Given that LPS produced by P. aeruginosa has shown to act as a ligand for TLR4108, 
future work could consider immuno-fluorescence (IF) experiments to explore Rab10 
localisation with TLR4 following P. aeruginosa infection, and investigate if LRRK2-dependent 
Rab10 phosphorylation results in any specific changes.  
Alternatively, it is possible that LRRK2 activation by P. aeruginosa is detrimental to the host 
cell response. By example, previous research involving infection of mouse macrophages with 
the Gram-negative intracellular pathogen S. Typhimurium revealed that LRRK2 promoted 
activation of the NLRC4-inflammasome, which enabled host defence through resultant 
caspase-1 and IL-1 β secretion51. Mechanistically, LRRK2 formed a complex with NLRC4, 
leading to NLRC4 phosphorylation at Ser533. However, whilst the NLRC4-inflammasome is 
key to the clearance of intracellular pathogens, other studies surprisingly found that NLRC4-
inflammasome activation by P. aeruginosa, an extracellular pathogen, decreased its clearance 
within mouse macrophages109. This was later revealed to be mediated through enhanced 
secretion of the pro-inflammatory cytokine IL-18, resulting in lung injury through excess 
neutrophil recruitment, and repression of beneficial IL-17 antimicrobial host response110. Thus, 
exploring the interaction of LRRK2 with the NLRC4-inflammasome during P. aeruginosa 
infection in both macrophages and neutrophils may provide important insights into 
understanding whether its role is beneficial or deleterious in the host cell response.   
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Finally, based on my findings of increased LRRK2-dependent Rab10 phosphorylation in CF 
sputum neutrophils (Figure 3.4), it is important to consider that LRRK2 ‘hyperactivation’ could 
be involved in the maintenance of chronic inflammatory states. Indeed, recent research 
revealed that LRRK2 expression was positively correlated with the severity of systemic lupus 
erythematosus (SLE), a chronic autoimmune disease, and LRRK2-deficient mice showed 
attenuated lupus-like pathology47. Given that CF patients have elevated hyperinflammatory 
states which uniquely predispose them to frequent infections and ineffective clearance of P. 
aeruginosa, exploration into whether this is maintained by LRRK2 activity could be ground-
breaking. Interestingly, some evidence has suggested that the defective CFTR channel 
protein in CF can itself induce inflammation in the absence of infection111, thus investigation 
into whether LRRK2 normally interacts with this protein, and how it could be affected by 
mutation, may be of interest. It would also be interesting to understand whether LRRK2 plays 
a distinct role in CF neutrophils, particularly concerning their altered migration and impaired 
phagocytic properties. Thus, novel insights of LRRK2 in CF pathobiology could open new 
ideas for CF treatment, such as trialling LRRK2 inhibitors in CF patients to observe if their 
intractable upper airway inflammation and pathogen burden can be reduced. Nevertheless, 
before these exciting possibilities can be considered further, increased research as well as 
better understanding of the safety profile of LRRK2 inhibitors are required.   
5.3 Project B Discussion 
5.3.1 Endogenous PINK1 could not be detected in peripheral blood neutrophils 
following CCCP activation 
For Project B, my overall aim was to investigate if I could stabilise and visualise endogenous 
PINK1 within peripheral blood neutrophils from healthy blood donors in 
immunoblotting/immuno-precipitation (IP) experiments following 10µM CCCP treatment. My 
main experimental outcome was that endogenous PINK1 could not be detected in either whole 
cell lysates or PINK1 immuno-precipitates of healthy human peripheral blood neutrophils 
following up to 12 hours 10µM CCCP stimulation (Figure 4.6). Whilst my initial experiments 
with whole cell lysates revealed a band around the expected molecular weight for full length 
PINK1 (~63kDa) that emerged with increasing CCCP time-course (Figure 4.2), this band was 
also observed in HEK293 PINK1 knockout cells, suggesting it as a non-specific band detected 
by cross-reaction of other abundant proteins activated in peripheral blood neutrophils with the 
PINK1 Novus antibody.  
Recent work investigating PINK1 expression in CCCP-treated mouse platelets similarly 
revealed that multiple bands around the predicted molecular weight of PINK1 were seen in 
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both WT and KO PINK1 platelet lysates using several different PINK1 antibodies, including 
the PINK1 Novus used within this project112. However, whilst PINK1 protein expression could 
be detected through IP experiments in WT PINK1 mouse platelets treated with CCCP for 6 
hours, I was unable to achieve this in the experiments I conducted (Fig. 4.6). This could be 
explained by potential expression level differences in PINK1 between blood cell type (platelet 
versus neutrophils), as well as PINK1 expression between species (mouse versus human). 
Indeed, it could be hypothesised that PINK1 mRNA expression is much lower in human 
neutrophils compared to mouse platelets, and hence more drastic and longer time-courses of 
mitochondrial depolarisation may be needed to detect any observable changes in PINK1 
protein activation in human neutrophils. 
5.3.1 Project B limitations and future work 
Although my results from Project B suggest that human peripheral blood neutrophils are not 
an ideal cell type to visualise endogenous PINK1 activation, further experiments are required 
to overcome existing project limitations and validate findings. Firstly, one of the limitations of 
my work was not independently establishing whether PINK1 mRNA transcripts were present 
within the neutrophil lysates isolated from human peripheral blood. Although previous 
experiments published within the Expression Atlas database revealed that PINK1 mRNA is 
expressed in several types of human neutrophils (Fig. 4.1), quantitative RT-PCR experiments 
on both untreated/CCCP treated peripheral blood neutrophils to assess PINK1 mRNA 
expression should be considered for future experiments. In addition, it would be interesting to 
investigate for any time-dependent changes in PINK1 mRNA transcription following CCCP 
treatment in neutrophils. Whilst previous research showed that PINK1 transcription was not 
increased in HeLa cells treated with CCCP for 1 hour  compared to DMSO controls81, it is 
possible that PINK1 transcription and expression is controlled differently between cell types, 
and may require longer CCCP treatment for any observable changes in PINK1 transcription. 
Another limitation of my work was not being able to confirm that CCCP induced mitochondrial 
membrane depolarisation, despite observing significant cell death in neutrophils treated with 
CCCP for 20 hours (Figure 4.2). Immunoblotting for OPA1 as an indirect readout of 
mitochondrial membrane depolarisation is used for many cell models, whereby cleaved forms 
of OPA1 can be detected upon mitochondrial damage. However, in initial experiments 
involving OPA1 immunoblotting in CCCP-treated neutrophils, I did not obtain clearly cleaved 
bands, potentially due to non-specific binding with other proteins in the same molecular weight 
region (data not shown). Using a different OPA1 antibody that recognises a different epitope 
of OPA1, or using a different marker of mitochondrial depolarisation, such as ATP5A, may 
therefore be worth assessing for future experiments. Alternatively, flow cytometry analysis 
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(FACS) using Mitotracker as used in previous work113 could also be considered, in which 
mitochondrial depolarisation following CCCP treatment can be directly visualised based on 
the intensity of a fluorescent dye taken up by neutrophils, which will be reduced in depolarised 
mitochondria.  
It is also possible that the length of CCCP treatment I used for mitochondrial depolarisation 
was not sufficient to stabilise endogenous PINK1 for detection with the current available tools, 
if present, in neutrophils. Hence, repeating the experiment with CCCP time-courses between 
12-20 hours would provide assessment for optimal PINK1 activation balanced with 
maintaining cell integrity. Using other mitochondrial inhibitors, such as Antimycin/Oligomycin, 
may also be more appropriate given that their action is targeted to the mitochondrial 
respiratory chain, rather than CCCP which creates generalised cellular membrane damage 
and thus may be too harsh on neutrophils. However, previous experimentation using 10µM 
Oligomycin in human peripheral blood neutrophils was reported to result in a small increase 
in apoptosis (~5%) after 20 hours of treatment (personal communication), hence may still 
present similar issues as observed with CCCP use.  
The experiments I conducted in this project only investigated for PINK1 activation in whole cell 
neutrophil lysates. Importantly, the amount of PINK1 present within the mitochondria itself is 
crucial for study of the PINK1/Parkin pathway in neutrophils, as it is here that its stabilisation 
and activation is being measured. Hence, future work could consider mitochondrial 
fractionation of stimulated neutrophil lysates, which would enrich integral mitochondrial 
proteins and thus reduce the amount of non-specific proteins present detected by PINK1 
antibody for Western blotting.  
Whilst I utilised the best currently available antibody tools to detect PINK1/Parkin activity for 
my experiments within Project B, it is possible that they were not sensitive enough to detect 
the low levels of PINK1/pUb in stimulated peripheral blood neutrophils, which may have been 
below the threshold of detection. Although other commercial and in-house mouse monoclonal 
PINK1 antibodies trialled on HeLa cell control lysates did not prove superior in PINK1 detection 
compared to use with the PINK1 Novus (data not shown), there may be different sensitivities 
in the PINK1 Novus antibody in detecting endogenous PINK1 in peripheral blood neutrophils. 
Previous data from the Expression database also indicated that Parkin mRNA expression was 
significantly low (Fig 4.1), which was corroborated with the results in Figure 4.3 which could 
not detect Parkin in stimulated neutrophil lysates upon probing with the anti-Parkin antibody. 
However, using other readouts of Parkin E3 ligase activity in activated neutrophils could be 
considered for future work, such as antibodies against ubiquitylated forms of CISD1 or Miro1. 
More excitingly, future work should consider using the Rab8A Ser111 antibody recently 
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developed by members of the Muqit lab, which is anticipated to provide a highly sensitive and 
specific readout of PINK1/Parkin pathway activity based on the indirect phosphorylation of 
Rab8A at Ser111 by PINK1.  
Finally, it is possible that neutrophils have distinct mechanisms independent of the 
PINK1/Parkin pathway which regulate mitophagy, hence mitochondrial stimulation may not 
activate the pathway to the same extent as observed in other control cell types. Supportively, 
previous research revealed that healthy human peripheral blood neutrophils do not complete 
mitophagy upon mitochondrial damage, but instead have two complementary pathways 
involving 1) the extrusion of inner mitochondrial components, including mtDNA, which is 
devoid of oxidized residues, followed by 2) mtDNA targeting to lysosomes for degradation 
after it is oxidised and dissociated from transcription factor A mitochondria (TFAM)114. Indeed, 
1hr CCCP treatment in peripheral blood neutrophils was shown to increase mtDNA extrusion 
with a concomitant reduction of TFAM intracellular levels. Interestingly, in monocytes but not 
neutrophils, CCCP treatment promoted the upregulation of several transcripts related to 
autophagy activation (ULK2), autophagosome trafficking (Rab27a and Rab4a), fusion (NSF, 
SNAP23, SNAP29, STX2, and LAMP2) and lysosome activation (Presenilin-1)114. In contrast, 
TOM1, which participates in autophagosome maturation, was significantly reduced in 
neutrophils following CCCP treatment. Surprisingly, the authors of this study did not 
investigate for any changes in the gene or protein expression of PINK1 or Parkin, where it is 
possible that their role in mitophagy is overshadowed by upregulation of other transcripts 
relevant for other parallel pathways in peripheral blood neutrophils. This would be interesting 
for future work to assess, as well comparing for any differences in the activation of the 
PINK1/Parkin pathway in human derived monocytes or macrophages, given that mitochondrial 











6. CHAPTER 6 - CONCLUSIONS  
To conclude, my work for Project A and B presented within this thesis explored key aspects 
of the PD associated LRRK2 and PINK1/Parkin signalling pathways within immune cells.  
With regards to Project A, my results revealed differential effects of LRRK2 activation in 
response to P. aeruginosa infection, whereby LRRK2-dependent Rab10 phosphorylation and 
LRRK2 Ser935 phosphorylation was induced in human peripheral blood neutrophils and 
mouse BMDMs following infection, respectively. Furthermore, my preliminary investigation 
into LRRK2 activity within sputum neutrophils isolated from infected CF patients revealed high 
levels of LRRK2-dependent Rab10 phosphorylation, providing a supportive basis for a large 
clinical study in CF patients to investigate changes in LRRK2 activity during the natural time-
course of infection. Exploring upstream and downstream immune signalling pathways from 
Rab10 phosphorylation or LRRK2 Ser935 phosphorylation may also help piece together 
relevant cell-specific or host-specific roles of LRRK2, and thus provide novel insights into the 
relationship between P. aeruginosa infection and LRRK2 cellular function.  
Crucially, the key question remaining is whether LRRK2 kinase activation is beneficial or 
detrimental to the host response during infection. As explored in my project, the answer is 
likely to be complex; based on pathogen, cell and host specific factors, as well as potential 
differences in LRRK2 function existing between healthy individuals and those with conditions 
impairing the immune system. Thus, whilst improved understanding of LRRK2 function in the 
context of infection and inflammation will provide benefits for understanding PD pathobiology, 
it may also open up novel opportunities for treating chronic and inflammatory diseases, like 
CF, if LRRK2 activation is also revealed to play a role in its pathogenesis.  
With regards to Project B, my findings revealed that PINK1 protein activation or expression 
following CCCP treatment of human peripheral blood neutrophils could not be visualised 
through either immunoblotting or immuno-precipitation experiments. Whilst my results 
therefore do not promote peripheral blood neutrophils as a useful human cell resource for 
investigating the PINK1/Parkin activation pathway, future experiments adapted to use different 
mitochondrial depolarisers, treatment timings, mitochondrial fractionation experiments or 
antibody readouts are required to confirm the current findings. Ultimately, finding appropriate 
cell sources to directly monitor endogenous PINK1/Parkin pathway activation in humans will 
provide better knowledge on its overall functioning and regulation, and engender greater 
insight into how its dysfunction can precipitate PD pathology. Importantly, this knowledge 
could enable stratification for appropriate PD patients that may benefit from elusive future 
drugs that aim to re-activate the damaged PINK1/Parkin pathway, and thus provide a direct 
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